3 Primary Liver Cancer: Chemical Carcinogenesis

*Sheeno P. Thyparambil PhD,
Ricky D. Edmondson, PhD, and
Yvonne P. Dragan, PhD*

CONTENTS

ABSTRACT

Liver cancer is an important form of cancer worldwide ranking in the top ten in both incidence and mortality *(1)*. Over 200,000 new cases of primary hepatocellular carcinoma are diagnosed worldwide each year *(1)*. The American Cancer Society predicts over 22,000 new cases of liver and bile duct cancer and that nearly 18,000 individuals will die of this disease in the year 2009 *(2)*. In the United States and Europe, primary liver cancer is fairly rare, but in some parts of the world, it is the primary type of cancer observed *(1)*. Environmental influences, including carcinogen exposure, are believed to contribute to its distinct geographical distribution pattern *(3)*. Although rare genetic disorders can contribute to liver cancer development, ethanol and dietary factors are known to contribute to its incidence and progression *(3)*.

The prevalence of liver cancer and its high mortality rate indicates the need for appropriate animal models of this disease in order to develop treatment and intervention strategies. In addition, the liver is the primary site for cancer induction in the bioassays used for carcinogen testing indicating the necessity for extrapolation of neoplasms that arise at this site in animals to man. The utility of defining common biomarkers for the conversion of benign to malignant transition will assist in developing appropriate inter-species extrapolation for risk assessment. The inclusion of early lesions from pre-clinical models will permit assessment of the ability of methods to develop appropriate risk assessment. In addition, analysis of liver cancer development is a useful model for study of the carcinogenic process of solid tumors that arise in both humans and animals. The influence of genetic background and environmental factors on neoplastic development is readily studied in rodent models of this disease.

While genetic factors can contribute to primary liver cancer development, environmental factors have an important role in human liver cancer development. The liver is exposed to ingested materials and has a high level of metabolism. The liver is susceptible to liver cancer development by chemicals and rodent liver has been used as a model to understand the role that chemicals play in liver cancer development and progression. In the human, cirrhosis is an important contributor to most primary liver cancer development. Viral hepatitis can lead to cirrhosis and certain chemical exposures to contribute to this baseline liver disease and can exacerbate the potential for liver cancer. These include aflatoxin, ethanol, and potentially other dietary constituents (limited antioxidant intake (selenium, Vitamin E), iron excess, and others). Ethanol and NASH can contribute to the development of cirrhosis and likewise can lead to HCC development. Chemicals that can increase the incidence of neoplasms in animals can be classified into genotoxic and nongenotoxic modes of action. The effects of agents with a carcinogenic potential are dose dependent. Understanding the biological basis of the changes that occur during the cancer induction and progression process, as well as the changes that chemicals induce in the liver will improve our knowledge of the steps and stages in the pathogenesis of primary liver cancer.

Key Words: Chemical carcinogens; primary liver cancer; HCC; genotoxins; nongenotoxins

1. INTRODUCTION

The biology of the liver, the biological processes involved in cancer development, and the etiological factors involved in liver cancer development provide a focus on the early processes and signaling pathways important

in primary liver cancer development. Perhaps, the most important point to consider is the cell population at risk for initiation of the cancer process in the liver. Since most hepatocytes are in Go phase, first proliferation must be stimulated. Under normal conditions, single cell death is followed by replacement of that hepatocyte. One hypothesis is that cancer stem cells are bipotential and can be stimulated to proliferate *(4)*. Their (oval cells) outgrowth can occur under situations where a large percentage of the liver is damaged. The stem cells then differentiate into hepatocytes or cholangio-cytes depending on the degree and duration of damage. Agents that cause extensive damage to the liver can result in neoplastic changes that are fetal in nature. A second hypothesis is that mature hepatocytes are the cell popu-lation at risk for early preneoplastic changes *(5)*. Mature hepatocytes can develop into focal areas of proliferation that in turn can become nodu-lar areas of hyperplasia. In this case, both poorly differentiated, small cell lesions (that are primarily diploid) and large cell, more highly differentiated (tetraploid or higher ploidy) lesions develop *(6)*. Understanding the etiol-ogy, proliferative and differentiation cues for the liver, and the mechanisms of the carcinogenesis process in the liver is key to understanding the role of chemicals in the development of HCC (Table 1).

Chemical, biologic, and physical agents can contribute to cancer develop-ment. Perturbations in single cells lead to the focal outgrowth of putatively preneoplastic lesions. The altered areas can evolve into nodular hyperplasia, focus in nodule pathology, and areas of frank malignancy *(6)*. To determine the contributions of chemicals to the carcinogenic process in the liver, a variety of animal models have been developed. Since the liver is the pri-mary site for cancer induction in the bioassays used for carcinogen testing, there is a need for extrapolation of animal neoplasms that arise at this site to man. The utility of defining common biomarkers for the conversion of benign to malignant transition will assist in developing appropriate inter-species extrapolation. The inclusion of early lesions from preclinical models will permit assessment of the early changes that occur prior to the onset of clinically detectable disease to our understanding of HCC.

2. LIVER CANCER IS AN IMPORTANT BIOLOGICAL PROBLEM

Liver cancer is an important form of cancer worldwide ranking in the top ten in both incidence and mortality *(7, 8)*. Hepatocellular carcinoma (HCC) is the primary form of liver cancer. Primary liver cancer is the sixth most common form of cancer (626,000 cases/year) in terms of incidence *(9)*. In addition, it is the third most common cause of death (598,000 deaths/year) from cancer *(10)*, with 80% of cases (and deaths) occurring in developing

Table 1
Different Chemicals and Their Role in Development of HCC

Chemical/toxin	Mode of action	Biological effects
Aflatoxin B1	AFB1 forms covalent bonds with DNA, binds to free amino groups of amino acids	Carcinogenic, mutagenic and toxic effects
Alcohol abuse and tobacco	Evidence for direct action is not clear. The abuse exacerbates the action of HCV, HBV, cirrhosis-mediated HCC	It is a risk factor for the progression of HCC
Oral contra-ceptive	Requires chronic exposure (>5 years) to mestranol, ethinyl estradiol. Mechanism not clear	Benign hepatic adenomas. Prolonged use with high doses and potency leads to HCC
Dioxin	Acts via AhR which binds to arnt and ultimately results in overexpression of many anti-apoptotic genes. It also induces many metabolizing enzymes that are responsible for toxic intermediates	Enhances proliferation and inhibit apoptotic processes. Causes increase in the size of the liver and ultimately causes liver damage
Phenobarbital	Mechanism is tightly linked with induction of CYP2B1 and the activation of CAR. Low levels of TGFβ1 and elevated levels of anti-apoptotic Bcl2 have been reported.	PB is a liver tumor promoter in rodents
PPAR agonists	The agonists increase TGFβ1 aiding hepatocarcinogenesis	PPARα agonist produces liver tumors in rodents. It causes hepatomegaly and cell proliferation

countries. Surveillance Epidemiology and End Results (SEER), the National Cancer Institute's statistical unit, estimated that 19,000 new cases of liver and intrahepatic bile duct cancer were diagnosed and nearly 17,000 people died from this disease in the United States in 2007 *(2)*. Understanding the

processes that contribute to the cancer development process are important components of determining how and where certain compounds contribute to liver cancer development and progression. Environmental influences, including carcinogen exposure, are believed to contribute to the distinct geographical distribution pattern of primary liver cancer *(11)*. Another important cause of primary liver cancer in humans is viral with both HCV and HBV infection contributing to its incidence. According to NHANES 3, the number of individuals with chronic HCV infection is greater than 3 million in the part of the US population sampled *(12; 13)*. Chronic infection with hepatitis C virus (HCV) is known to be a major risk factor for development of hepatocellular carcinoma (HCC). In general, HCC develops only after two or more decades of HCV infection and in those with advanced fibrosis *(14)*. Cirrhosis is also an important factor associated with the development of primary liver cancer and hence is an important control for liver cancer biomarker development, most liver cancer arises in the context of cirrhosis. In the United States, less than 30% of HCC is viral in etiology. Excess alcohol use and diabetes mellitus are independent risk factors for liver cirrhosis and are associated with liver cancer development in the United States *(15)*. In addition, smoking may contribute to the risk of liver cancer development. The residual 10% of attributable risk of HCC may be due to or influenced by hereditary metabolic disease factors (such as hemochromatosis). Although rare genetic disorders can contribute to liver cancer development, ethanol and dietary factors are known to contribute to its incidence and progression *(2, 3)*. The prevalence of liver cancer and its high mortality rate indicates the need for appropriate animal models of this disease in order to develop treatment and intervention strategies. In addition, the pathogenesis of primary liver cancer development for different etiologies needs to be better delineated. The influence of genetic background and environmental factors on neoplastic development is readily studied in rodent models of this disease.

3. CHEMICAL CARCINOGENS

Carcinogenesis can be induced by physical, biological, or chemical means. Agents that act to increase the incidence of cancer in appropriate organisms compared with concurrent and/or historic controls are considered carcinogens. The identification of a carcinogenic potential for an agent delineates the conditions of exposure (dose, time, and duration) under which the agent may induce cancer. Animals are surrogate models of humans since they possess similar physiology and biochemistry. This similarity is not absolute; hence any hazard detected must be examined in the context of human relevance in order to understand the conditions of exposure that may pose a plausible risk to humans. Each human HCC is detected

at different points along the pathogenesis continuum. Several factors are important for cancer development including a loss of normal growth control with contributions from inhibition of apoptosis and enhanced but altered proliferation control *(16)*. In addition, an altered differentiation status can contribute to cancer development and progression. The morphology and certain aspects of the natural history of rodent and human cancer are coincident although the etiology and the exact molecular pathogenesis may diverge between rodents and man. Although several parallel pathways may be induced, the pathway for cytogenetic alterations observed in a specific cancer type is similar in rats, mice, and men. The latency period between initiation of early precancer changes in a single cell and its selection for malignant growth comprises the reversible stage of tumor promotion. In the human, exposure to dietary contaminants such as aflatoxins, as well as calorie overload, ethanol over use, and methyl deficiency can contribute to the risk of primary liver cancer. Certain metals (iron and copper) have been associated with an increased risk of primary liver cancer. Thus, a number of classes of chemical agents can increase the incidence of hepatic neoplasms depending on their dose and duration of exposure.

3.1. Genotoxic Carcinogens

Chemically induced carcinogenesis has been examined experimentally for less than 100 years *(17, 18)*. Initial studies provided the compounds typically in the diet for extended periods of time. For example, the studies of Sasaki and Yoshida *(19)* demonstrated that chemicals could cause hepatic neoplasms in animals. Provision of *o*-aminoazotoluene in the diet led to liver neoplasms in rats. Similarly, Kinoshita *(20)* demonstrated that feeding 4-dimethylaminoazobenzene to rats resulted in liver neoplasms. These findings suggest that agents can be carcinogenic at sites distant from their initial application. Importantly, analogues of these agents have also been examined allowing some structural information to be gathered about the properties of agents that have a carcinogenic potential *(21)*. There is some tissue specificity for carcinogenic action as polycyclic aromatic hydrocarbons are not typically carcinogenic to the liver (except in some circumstances during the neonatal period), while they are to the skin *(22)*. Similarly, certain azo dyes, while carcinogenic to the liver, do not have this activity in the skin *(23)*. The agent 2-acetylaminofluorene but not its related regioisomer, 4-acetylaminofluorene, is carcinogenic in the rodent liver *(24)*. However, dialkyl nitrosamines and several analogs are cytotoxic to the liver and are carcinogenic in rodents and many other mammals *(25)*. These activities are dose dependent and high doses induce acute toxicity, while lower doses are tolerated but can result in neoplasms if the dose and duration of exposure is sufficient. Similarly, aflatoxin produced by the fungus *Aspergillus flavus*

is acutely cytotoxic. This agent is also carcinogenic in all species examined, although the mouse is relatively resistant to its carcinogenic action *(26)*. A variety of other agents in food can also be carcinogenic to the liver including certain mycotoxins *(27)* in addition to aflatoxin (fumonisin in rodents) and pyrrolizidine *(28)* alkaloids (found in comfrey and riddelline). In addition, a dearth of antioxidants and a lack of lipotropes *(29, 30)* can lead to cancer development in the rodent.

3.1.1. DNA Adducts

This initial class of agents is capable of altering the genetic material either directly, through one of its metabolites, or through perturbation of the processes controlling its actions. Agents that modify the DNA can initiate the carcinogenic process *(31)*. These agents can be metabolized to form DNA adducts or may directly form them. Alternatively, such agents can alter the methylation status of the DNA. In each case, the DNA is modified in a manner that results in heritable changes. In the case of DNA adducts coupled with cell proliferation mutations can result *(32)*. Such mutations can alter the function of selected genes, in some cases inactivating them and in other cases enhancing their activity *(33)*. The dose and duration of exposure of an agent is an important contributing factor to understanding the carcinogenic risk of an agent at doses to which humans are exposed. Many agents with a carcinogenic potential can be metabolized to an electrophilic form. These reactive metabolites can bind to cellular nucleophiles including DNA, RNA, proteins, and lipids *(23)*. The biological consequences of these actions differ. Early studies by James and Elizabeth Miller *(34)* demonstrated that certain carcinogenic agents did not directly bind to proteins, but that following incubation of the compound with tissue extract, the compound or some derivative could be found bound to protein in normal liver but not in the resulting neoplasm. This harbinger of metabolic activation or reactive metabolite formation would lead to the determination that the cell could metabolize some compounds to a reactive form. For example, AAF is metabolized by ring hydroxylation *(35)* and by N-hydroxylation *(36)*. The *N*-hydroxy metabolite can be demonstrated to be more carcinogenic than the parent AAF *(23)*. The *N*-hydroxy AAF is further metabolized by esterification with glucuronyl, acetyl, and sulfate groups. Although conjugation can lead to inactivation of reactive metabolites, in certain cases it can form more reactive agents with facile leaving groups. This is the case for some esters of *N*-hydroxy AAF *(23)*. In addition to the formation of reactive metabolites, certain agents can form free radicals *(37)*. Free radicals have no charge, but have an unpaired electron that makes them reactive. This process can be facilitated by the presence of free iron or copper. Endogenous processes can form free radicals and metabolism of certain carcinogenic agents can also lead to their generation *(38)*. Many agents with a carcinogenic potential can be metabolized to

reactive forms providing a mechanism to understand species differences and individual risks. Understanding the structural basis for metabolic activation permits the prediction of agents that are likely to be directly genotoxic or that can be metabolized to a genotoxic form. In addition, it generates a physicochemical basis for understanding mutagenesis at specific sites in the DNA and in specific tissues. Careful analyses of structures that are positive in rodent bioassays have yielded reactive groups that yield structural alerts for carcinogenic risk *(39, 40)*.

Aflatoxin B1-8,9-epoxide

Attacks N^7-guanine of the DNA

Aflatoxin-N^7-guanine (DNA adduct)

3.1.2. MUTATIONS AND THEIR CONSEQUENCES

The reaction of electrophilic substances with the DNA results in physicochemical changes in the DNA. The high prevalence of cancer in individuals with an inability to remove DNA adducts in DNA repair deficiencies indicate the important role of DNA damage in cancer induction *(41)*. Similarly, the high incidences of mutations in selected genes in animal models of cancer further demonstrate that DNA damage is the basis of early cancer development *(33)*. Alkylation of DNA can occur by carcinogenic agents that can be metabolized to reactive forms. In this case, the reactive metabolite can covalently adduct to the DNA *(42)*. For example, aflatoxin B1 can be

metabolized to 8,9-epoxide of AFB1, which then binds to N7 guanosine leading to mutations *(43)*. Mutation of G to T can occur at multiple sites, most notably at 249Ser of P53 *(44)*. Methylation, ethylation, and other alkylations can occur with each of the bases as well as the sugar and phosphate backbone *(45, 46)*. Direct-acting electrophiles can bind to the N7 of guanine, while softer electrophiles can bind to the ring oxygens of the bases. Formation of bulky adducts can occur on the purine ring, while small alkylations can occur more ubiquitously. At lower exposures, selective alkylation can occur, which may or may not be repaired. The presence of DNA adducts and the repair of these lesions can result in mutation. As the adduct burden increases with increased dose/duration of exposure, the repair can be more extensive and over a greater span of the DNA. In addition, as dose/duration increases more cell types may become involved as metabolism shifts and conjugation reserves are depleted. Repair can outpace adduct conversion to mutations under some circumstances. When the lesion is repaired, either the base is removed or a larger segment of DNA is removed. Each of these processes can have different rates and consequences and each is dose dependent.

Point mutations, frameshift mutations, chromosome aberrations, and aneuploidy can occur following chemical administration. Because of the

degree of adduct formation, the site of adduct formation, the ability of adducts to be repaired, and the degree of metabolism to reactive forms, differential activity can be seen in individual cells, tissues, organisms, and species. One consequence of the presence of DNA adducts is cell death. Apoptosis is observed at lower concentrations followed at higher exposures and degrees of damage by necrosis. Direct-acting carcinogens are reactive without requiring metabolic activation and are often carcinogenic at the sites of exposure in multiple species *(47)*. Methylation or ethylation of DNA can lead to base mispairing *(45, 48)*. Because these simple alkylations are similar to or can result from endogenous processes, they are not as actively repaired. In part, the more persistent DNA adducts/lesions are the ones that have an important mutagenic consequence. For example, ethylating agents can adduct at O6 alkylguanine and O4 alkylthymidine. The O6 adduct is readily repaired, while the O4 adduct is more persistent leading to base mispairing with different consequences for both lesions *(49, 50)*.

The consequence of bulky adduct presence is to block DNA synthesis resulting in noncoding *(46)*. However, the DNA synthetic machinery can bypass such lesions placing in its stead the most abundant nucleotide, generally an adenine *(51)*. Since bulky adducts are typically at guanines, this is a useful strategy that can, however, result in more marked consequences when more than one base is affected or the adduct was not at guanine. Using 2-AAF as an example, the parent is not mutagenic, but it can be esterified to the sulfate ester that is highly reactive; binding to the N7 of guanine as well as the N3 of guanine *(23)*. In contrast to the formation of a covalent bulky adduct by 2-AAF that distorts the DNA structure, 2-aminofluorene, which also forms bulky adducts at the same sites, sits outside of the helix and does not distort it. As a consequence, 2-AF can induce point mutations, while 2-AAF can lead to frameshift mutations *(52)*. Biological consequence of the presence of DNA adducts is a function of their persistence in the DNA *(53)* and impacts their tissue and species specificity. The persistence of DNA adducts in viable cells has consequences when cell proliferation occurs to fix the mutation before repair can occur *(32)*. Once the mutation is fixed, its location in the genome, the expression of that DNA, and the importance of the affected gene in that stage of the differentiation of the cell, both impact its consequent mutation and the ultimate consequence of a given adduct. Although susceptibility to cancer induction can be modified by polymorphisms in DNA repair genes *(41)*, carcinogen metabolism *(54)*, and immune system *(55)* differences, genes that regulate cell growth and proliferation are more frequently the targets of carcinogens. Both protooncogene and tumor suppressor gene function can be altered by carcinogen exposure *(56–58)*. For example, oncogenes such as Ha-ras can be activated by a single point mutation *(59)*. Activation of Ha-ras is an important mechanism of HCC induction and development in the mouse *(33, 60)*, but not in rats or humans

(18). In the liver, activation and mutation of β-catenin (and possibly axin) is an important aspect of some types of liver cancer *(61, 62)*. Similarly, mutations in HNF1 can result in loss of differentiation status as evidenced by loss of expression of a number of drug-metabolizing genes in the neoplasm. Although mutations have been observed in a number of genes in HCC development and progression, only a few genes have non-random mutations. The genes found in HCC that contain mutations include p53, IGF2R, CycD, CycA, BCL10, met, RB, TRα, or β *(6)*. Etiologic agents have been examined with respect to the resulting mutations observed in specific genes including p53, β-catenin, and HNF1. There appear to be multiple pathways that can lead to HCC initiation and progression *(62)*.

Endogenous DNA modifications can be perturbed and this perturbation can contribute to chemical carcinogenesis. Hydroxylation of DNA bases can also occur both through endogenous processes and by certain DNA damaging agents *(63)*. Repair processes for oxidative damage are pervasive in most cell types nonetheless oxidized bases can persist *(64)*. Although all of the DNA bases can be oxidized, the most common are 8-hydroxy deoxyguanosine *(65)* and 5-hydroxymethylthymine *(66)*. These oxidative bases likely arise through endogenous processes *(67)* and they are readily repaired. The most prevalent endogenous modification of DNA is methylation of deoxycytidine *(68, 69)*. Chemical carcinogens can perturb this process by adduct formation, altered one-carbon pools, single strand break formation, or inactivation of the enzymes involved in the methylation process *(70)*. Diets deficient in lipotropes can result in marked steatosis followed in time by HCC formation in rodents *(30)*. Methyl-deficient diets can result in DNA hypomethylation. Global hypomethylation results in re-expression of genes in general, while hypermethylation results in their silencing *(71)*. Perturbation of nucleosomes, minor and major groove protein binding, and the DNA repair process can likewise lead to DNA perturbations. The presence of a DNA adduct does not mean that a mutation will occur, but it does increase the probability.

3.1.3. THE ROLE OF CELL PROLIFERATION IN CANCER INITIATION

The presence of DNA adducts coupled with cell proliferation can lead to mutation. This process is called fixation wherein the mutation is fixed when an adduct or other DNA alteration persists through a cycle of DNA synthesis *(32)*. Thus, the rate of cell proliferation and DNA synthesis can impact DNA damage *(72)*. In situations where repair processes are normal, high rates of cell proliferation can still lead to mutations. Inherited defects in DNA repair lead to an increased risk of neoplasia *(46)* in many cell types especially in the GI tract with its high rate of exposure to potentially mutagenic agents and its high rate of proliferation. Hepatocytes turn over slowly by comparison

except in circumstances of persistent inflammation induced by hepatitis (viral, alcohol, or drug induced). DNA polymerases are not completely faithful in their replication of the DNA *(73, 74)*. Since a variety of types of DNA damage can occur, many processes exist to remedy their activity. Excision repair can remove either a modified base or nucleotide. The presence of an adduct will result in excision and repair with more bases removed and potentially misrepaired for nucleotide excision compared with base excision repair. Single strand breaks are readily repaired. The repair of double strand breaks is more problematic *(75)* and a nonhomologous end joining process is used that is error prone *(76)*. Mismatch repair can occur when bases are mispaired or when it appears that they are mispaired due to the presence of a DNA modification *(77)*. Perturbation of the mismatch repair process can result in mutations. Larger DNA damage including amplifications, deletions, and aneuploidy can occur. Agents that lead to these lesions contribute to the carcinogenesis process by altering gene dosage of critical genes and/or perturbing their expression. Although mutations alone do not lead directly to neoplasia, they can contribute to the process when they occur in genes critical for cell survival, proliferation, apoptosis, and differentiation status.

3.2. *Non-Genotoxic Mechanisms of Chemical Carcinogenesis*

A variety of compounds other than mutagenic agents can contribute to liver cancer development. These agents have in common the ability to alter cell survival either by increasing cell proliferation or decreasing apoptosis. Agents that have this activity include those that cause cytotoxicity and those that perturb signaling pathways associated with growth factors, some of which act through nuclear receptors *(18, 78)*. Certain agents are cytotoxic at either high doses or with chronic administration *(79)*. These agents such as chloroform do not pose a risk when exposure occurs below the threshold for cytotoxicity *(80)*. For example, chronic high dose ethanol consumption results in high levels of acetaldehyde generation *(81)*. Aldehydes can covalent adduct to proteins through Schiff base reactions and with other cellular components. In addition, CYP2E1 that generates acetaldehyde is loosely coupled to oxidoreductase resulting in the generation of reactive oxygen species. Acetaldehyde can result in exocyclic etheno DNA adducts *(82)*. The resulting oxidant damage and lipid peroxidation can lead to chronic hepatitis. In addition, the marked steatosis that can occur in conjunction with excess alcohol consumption may perturb the insulin/IGF1 signaling pathway of cell survival in the liver *(83)*. Similarly, the one-carbon cycle with eventual folate/choline depletion can contribute to cancer development *(84)*. Ethanol overconsumption in conjunction with HCV increases the risk of cancer development *(85)*. In addition, alcohol abuse in the context of hemochromatosis increases both cirrhosis and HCC risk *(86)*. In part this

may be due to increased oxidant stress in the presence of both increased lipid deposition and increased iron. Low alcohol intake does not appear to be associated with an increased risk of HCC, while higher levels are associated with an increase in risk of both cirrhosis and HCC *(87)*. In some parts of the world, alcohol is made with moldy food staples containing other liver toxins that can compound the problem. Similarly, intake of high levels of iron in conjunction with alcohol can similarly exacerbate the oxidant stress in the liver leading to cirrhosis. Since cirrhosis is associated with more than 60% of HCC in the human *(8)*, this is an important pathway through which ethanol contributes to primary liver cancer development.

Studies in animal models indicate that agents that act through selected nuclear receptors are associated with the ability to regulate cell proliferation/survival, apoptosis, and differentiation can promote tumor development *(18, 26, 78)*. Such agents can promote the outgrowth of cells with genetic damage into preneoplastic lesions and hence can under certain circumstances of exposure increase the incidence of hepatic neoplasia in rodents and humans. Tumor-promoting agents are believed to alter the balance between proliferation and apoptosis in initiated cells relative to the normal surrounding cells *(88, 89)*. Studies with prototypical hepatic tumor-promoting agents including phenobarbital, PPARα agonists, and ethinyl estradiol indicate that a generalized mitosuppression of non-focal hepatocytes is an early and sustained activity of such agents. In addition, reversible alteration of gene expression is associated with tumor promotion. Furthermore, tumor promotion is reversible and exhibits a threshold *(26)*.

3.2.1. PHENOBARBITAL

Phenobarbital and related agents are not genotoxic, yet they can result in the development of cancer in susceptible organisms *(90)*. While selected mouse strains can develop neoplastic lesions following chronic exposure to phenobarbital or related agents, certain rat strains can develop adenomas and rarely adenocarcinomas after chronic exposure. At therapeutic doses, man does not appear susceptible to liver tumor development with chronic phenobarbital administration (c.f. *(91)*). Initiation–promotion studies indicate that phenobarbital has a promoting action *(92)*. Importantly, a dose-dependent promoting activity is observed that exhibits a threshold *(93)*. Interestingly, phenobarbital and related agents can increase the background proliferation rate transiently in the liver *(94)*. Specifically, phenobarbital increases the focal relative to the non-focal hepatic labeling index *(95)*. Importantly, phenobarbital promotes eosinophilic, but not basophilic lesions *(96)*. In addition, a mitosuppression can be observed in the non-focal hepatocytes *(97)*, while the discrete focal hepatocytes have an increased rate of proliferation compared with control hepatocytes or the surrounding normal appearing ones *(98, 99)*. Phenobarbital increased DNA synthesis and decreased

apoptosis in hepatocytes in vitro *(100, 101)*. Studies with phenobarbital showed that only the promoting dose resulted in changes in gene expression associated with apoptosis suppression and cell proliferation, while dose-dependent changes in selected drug-metabolizing agents were observed *(102)*. It has been suggested that the increased growth rate of the eosinophilic lesions compared with the surround is due to the decreased responsiveness of the altered focal cells to TGFβ family members responsible for apoptosis *(103)*. IGF2R modulates cell proliferation in response to insulin and IGF family members and apoptosis in response to TGFβ. The expression pattern is altered in focal compared with non-focal areas of the liver for IGF2R and TGFβR *(104, 105)*. Phenobarbital can promote those initiated cells with a low level of TGFβR, while increasing ligand expression in surrounding hepatocytes *(103, 105)*. TGFβ is a potent mitoinhibitor of hepatocytes and phenobarbital increases this ligand in non-focal hepatocytes and TGFβ is increased at the protein level during mitosuppression induced by phenobarbital exposure *(103, 106)*.

Previous work has demonstrated that phenobarbital-like compounds cause the increase in gene expression of a number of genes including CYP2B1/2 *(107)* and is transcriptionally regulated *(108)*. The tumor-promoting action of this type of agent is correlated with the induction of CYP2B1 *(109)*; therefore, the mechanism underlying tumor promotion by phenobarbital and related compounds has been associated with the mechanism of CYP2B1 induction. Since a structurally diverse group of compounds act in a similar manner, it has been under consideration as to whether a receptor was responsible for this action. The constitutive androstane receptor (CAR) plays a role in the induction of CYP2B family members *(110)*. Agents that act to alter the metabolism of testosterone derivatives, specifically androstenedione, can alter endogenous activation of the CAR receptor *(111)*. There are two forms of CAR and phenobarbital can displace the ligand from CARβ *(111)*. Agents such as phenobarbital activate the CAR receptor to perturb gene expression *(112–114)*. Studies in knock-out mice indicate that certain genes are expressed or repressed when the CAR receptor is present while a separate set is affected when it is not present *(115–116)*. It is clear that CAR is associated with the gene expression acutely associated with phenobarbital exposure, but how this is associated with tumor promotion is unclear. CAR knock-out mice have been used to confirm that CYP2B expression is dependent on CAR *(114)*. Nonetheless, CAR knock-out mice are resistant to phenobarbital-induced hepatic tumor promotion *(117)*. Interestingly, chronic phenobarbital administration results in DNA hypomethylation that is CAR dependent *(118)*. The mouse strain susceptible to spontaneous and chemical carcinogenesis is sensitive to promotion by phenobarbital, while the resistant strain C57B6l6 is resistant. The tumors arising spontaneously in C3H mice are Ha-ras mutation positive *(119)*, lack

CAR, and are not promoted by phenobarbital *(120)*. These tumors lack CAR, but express β-catenin and are promoted by phenobarbital *(120, 121)*.

Nuclear receptors are frequent targets of drugs and of environmental chemicals. The function of these ligand-activated transcription factor receptors is to regulate endogenous metabolism; hence, homeostasis can be perturbed when their function is modulated. Drugs and environmental chemicals can alter the effects of multiple nuclear receptors due to their broad and overlapping substrate specificity. The interaction of nuclear receptors with coactivators and corepressors provides another level of control of their function within cells. The constitutive androstane receptor (CAR) is a nuclear receptor that regulates the expression of drug-metabolizing enzymes *(112–114)*. CAR is an important regulator of many genes involved in drug metabolism including a number of P450s, phase 2 enzymes, and transporters. Species specificity in response to CAR agonists has been detected although that of phenobarbital (PB) is only 1.5-fold (the human is less sensitive) and human CAR is not sensitive to the same bile acids as mice *(122)*.

3.2.2. Estrogenic Agents

In the human, certain estrogenic formulations can result in adenoma development and rarely in carcinomas. Estrogenic agents can be carcinogenic to rat liver, but tend to inhibit cancer development in the mouse liver. Estrogenic agents are clearly promoting toward the rat liver, but the basis for this action is unknown *(123–128)*. Estrogenic agents can increase cell proliferation in the rat liver and can induce focal proliferation with mitosuppression in the surrounding hepatocytes *(129, 130)*. Examination of altered gene expression during the mitosuppression observed with chronic ethinyl estradiol treatment demonstrated an increase in TGFβ and IGF2R/M6PR without a change in myc or CEBPα levels *(131, 132)*. The increase in TGFβ leads to CKI induction that may lead more directly to the mitoinhibition *(133)*. Similarly, EE exposure induces TGFβ1 expression. Hepatocytes with decreased levels of TGFβR are at a selective growth advantage compared to cells without this characteristic *(105)*. Hepatocytes that survive TGFβ exposure have decreased HNF4α activity, but increased fos, jun, myc, and ras levels *(134)*. Oncogene expression can confer tumor characteristics that TGFβ responsiveness can limit *(135)*; thus, loss of TGFβ responsiveness is permissive to acquisition of the tumor phenotype. In certain, hepatocarcinogenesis protocols administration of tamoxifen results in the regression of a component of the lesions suggesting an estrogen (and estrogen receptor) dependence for those lesions *(136–138)*.

Sustained estrogen receptor activation is known to increase the incidence of liver neoplasms in animals and humans. An increase in adenomas was observed in young women taking an early form of oral contraceptives (with a higher dose and different formulation to the current available forms). Rarely,

HCC was observed in women taking early formulations of estrogens for oral contraceptive purposes *(143)*. Estrogenic agents are effective tumor-promoting agents in the rat liver and their action to initiate cells through catechol estrogen formation *(144)* or induction of aneuploidy *(145)* needs to be assessed at physiological concentrations. For example, certain estrogenic agents can cause a burst of increased proliferation in the rodent liver *(146)*. This transient increase in cell proliferation is associated with stimulation of the estrogen receptor *(126, 141)*. There is a mitosuppression in the normal appearing hepatocytes, while the focal, putatively, preneoplastic hepatocytes have a sustained increase in proliferation *(131, 141, 146)*. Although the incidence of HCC in humans following chronic (greater than 5 years) estrogen exposure is low, the incidence is definable and permits one to anchor the incidence in rats where a clear carcinogenic response to high dose, potent carcinogens is observed under defined exposure conditions. This observation permits more accurate risk assessment from animal hazard identification studies. Extrapolation of potential for risk across species could be performed using the low incidence human tumor data as an anchor for the calculations.

Estrogenic agents have a carcinogenic potential at several sites including the mammalian liver *(144)*. Estrogenic agents are known liver tumor-promoting agents in the rat *(124, 125, 137)* and in the human *(145)*. There is an apparent threshold for promoting action *(146–148)*. The mechanism of tumor promotion is not known although an increase in focal proliferation and a decrease in focal apoptosis have contributing roles. Although tamoxifen has an estrogenic action in the liver that may contribute to its promoting action, the phenotypes of the liver lesions that arise with mestranol and tamoxifen treatment differ *(149)*. In addition, tamoxifen can inhibit the development of mestranol-promoted lesions indicating a divergent mechanism of action *(126, 137)*. The mechanism of estrogenic/antiestrogenic action for tamoxifen is only incompletely understood. While this action may in part be due to an interaction with the estrogen receptor, other factors may also be involved. For example, antiestrogens bind to sites other than the estrogen receptor including covalent binding to P450s *(150)*, tubulin *(151)*, and other interactions with "antiestrogenic binding sites" *(152)*. In addition, antiestrogens inhibit protein kinase C and calmodulin activity *(153)*. In addition, antiestrogens alter the production of several peptide growth factors including TGFα *(154)*, TGFβ *(155)*, and IGF1 *(156)*, and affect some calcium-dependent processes *(157)*. Estrogenic and antiestrogenic agents additionally alter cholesterol metabolism *(152)*. Tamoxifen appears to promote the diploid hepatocyte population *(158)*, similar to ethinyl estradiol *(159)*. The triphenylethylene antiestrogens have differential effects on the hepatic proliferative rate in the rat *(160, 161)*. In the liver itself, triphenylethylene antiestrogens have an estrogenic action; however,

these drugs are mixed agonist/antagonists in a species, strain, tissue, gene, and hormone status basis.

Mestranol is a synthetic steroidal estrogen that is metabolized *(162)* to the potent rat liver tumor-promoting agent, ethinyl estradiol *(154)*. Mestranol use in oral contraceptives was associated with an increased incidence of hepatic adenomas and a few hepatocellular carcinomas in young women *(144, 163–165)*. Studies in rats indicate that mestranol and its active metabolite ethinyl estradiol promotes the development of previously initiated liver cells through induction of elevated cell proliferation levels. Mestranol does not have a marked effect on P450 profiles in the liver *(166)*, but it can cause cholestasis *(167)* and clearly enhances liver growth *(166)*. Chronic administration of ethinyl estradiol results in mitosuppression of liver cells with selection of resistant hepatocytes for outgrowth *(129, 143)* and this in combination with its ability to increase cell proliferation *(126, 168)* is believed to be responsible for its tumor-promoting properties *(123, 125, 126, 129, 143, 148, 169, 170)*. Tumor promotion by ethinyl estradiol is effected through the estrogen receptor, since it can be inhibited by tamoxifen *(137, 138)*. At low doses and for short durations of administration, ethinyl estradiol can increase hepatic hypertrophy and a transient increase in cell proliferation *(126, 168)*, while with chronic administration a mitoinhibition is observed *(126, 129)*.

3.2.3. PPAR AGONISTS

The peroxisome proliferators-activated receptors (PPARs) are members of the steroid/retinoid receptor superfamily. Three mammalian nuclear receptors of the PPAR class have been isolated including PPAR alpha, delta, and gamma *(171)*. The PPARα receptor is a ligand-activated nuclear transcription factor that is responsible for the regulation of lipid catabolism *(172)*. The PPARα receptor and the retinoid X receptor nuclear receptor (RXR) can heterodimerize and bind to peroxisome proliferator response elements (PPRE) to alter the transcription of genes including those that are involved in lipid metabolism *(173–175)*. Peroxisome proliferators include structurally diverse chemicals that can activate the PPARα receptor including industrial chemicals, plasticizers, herbicides, and some lipid-lowering drugs *(175–177)*. Agonists of PPARα induce peroxisome proliferation *(177, 178)*, hepatomegaly *(177, 179)*, cell proliferation *(177, 180, 181)*, and liver neoplasms in rodents *(175, 181, 182)*. Although numerous theories exist regarding the mechanism of hepatocarcinogenesis in the rodent following chronic exposure to PPARα agonists, the mechanism is not fully understood. In general, PPARα agonists are not genotoxic and demonstrate a promoting activity *(183)*. Similar to other receptor-mediated, non-genotoxic rodent carcinogens, PPARα agonists, including WY14, 643, methylclofenapate, nafenopin, and clofibric acid increase the TGFβ1 ligand, while these agents

excluding clofibric acid increase expression of the IGFII/Man6P receptor *(184)*. Sustained PPARα receptor activation is required for induction of liver tumors, since PPARα knock-out mice do not develop hepatic neoplasms even after a 1-year exposure to PPARα agonists *(185)*. Similarly, peroxisome proliferation and gene expression regulated by PPARα are not altered by exposure to PPARα agonists in the knock-out mice *(185)*. The lack of carcinogenic action in the human relative to the rodent has been explored with human PPARα receptor knock-in mice *(186)*. Although the precise mechanism of the hepatocarcinogenesis of PPARα agonists in rodents is not fully understood, it appears to be dependent upon PPARα receptor activation *(187–189)*. Thus, PPARα agonists are non-genotoxic carcinogens that function through receptor activation *(190)* and appear to be carcinogenic in the rodent, but not in primates.

3.2.4. AhR Agonists

The aryl hydrocarbon receptor (AhR) is structurally distinct from the nuclear receptors and contains a bHLH-PAS domain *(191–193)*. The ligand-bound receptor interacts with arnt and this dimerization partner regulates the expression of specific genes. The ligand-binding domain of AhR is within the PAS domain. The PAS domain of AhR binds ligand, binds to a repressor (probably hsp90) and has some of the interaction function with arnt. The function of excess AhR ligand may be to block the function at the other sites of arnt binding. The low-affinity allele of AhR found in some mouse strains is similar to that observed in humans *(194–196)*. In addition, the transactivation domain part of AhR is highly divergent with only a 60% identity between rat and human *(196)*. This suggests that human gene expression in response to an AhR ligand will differ qualitatively as well as in magnitude from that in rats and mice containing the high-affinity AhR allele.

TCDD and related agents can induce a range of toxicities that may be mediated by AhR *(191)*. Dioxin lacks any genotoxic activity, yet increases the incidence of hepatic neoplasms in rats *(197)*. Dioxin can cause marked cytotoxicity at higher doses and this may contribute to its tumor-promoting activity. Activation of arylhydrocarbon receptor (AhR) by 2,3,7,8-tetrachlorodibenzoparadioxin (TCDD) and related compounds of the furan and PCB classes results in alterations in gene expression including an induction of CYP1A1 *(198)*. Although the role of CYP1A1, if any, in tumor promotion is unclear, CYP1A1 expression is a useful marker for ascertaining exposure to this class of compounds. Over 100 genes may be regulated by AhR activation *(199)*. Genetic differences between mouse strains have been used to demonstrate that TCDD-mediated liver tumor promotion is AhR dependent *(200)*. Transgenic mice overexpressing a constitutively active AhR are more sensitive to diethylnitrosamine initiation resulting in a higher yield of preneoplastic lesions than the genetically matched control

animals *(201)*. Knock-out animals have been generated *(202–204)*. The gene expression patterns *(205)* and toxicity *(206)* have been examined after acute but not chronic administration of TCDD to the knock-out animals. The genetic background of the animal is important for its potential to develop neoplasms in response to TCDD administration. Since a selection for neoplastic clones resistant to the toxic insult that permits their outgrowth occurs, Ha-ras-mutated hepatocytes might be resistant to Ahr-dependent toxicity. Liver tumors from TCDD-treated mice have a high incidence of Ha-ras mutations *(207)* suggesting that the C3H background would be exquisitely sensitive to TCDD-induced tumor promotion *(121)*.

Initiation–promotion studies in the rat *(208, 209)* indicate that there is a threshold for the promoting action of TCDD and related compounds. A variety of studies indicate that TCDD causes a generalized mitosuppression in the liver *(210, 211)*. However, an increased cell turnover in focal lesions was noted relative to the surrounding liver *(212)*. The initiated cell population is resistant to apoptosis *(213)*. Interestingly, the AhR null hepatocytes both secrete TGFβ ligands and are quite sensitive to the apoptosis induced by TGFβ *(214)*, indicating that AhR deficiency leads to increased TGFβ ligand production wherein selection for resistance to its apoptotic effects would permit promotion. Perhaps, TGFβR or processing of TGFβ through IGF2R would confer selective growth advantage to AhR–/– mouse hepatocytes that secrete TGFβ ligands. The AhR null mice have been used to demonstrate that the gene induction profile associated with AhR activation are altered *(205)* and the acute toxicities associated with AhR activation are diminished *(206)*. For example, CAR is increased by AhR activation *(215)*, while growth hormone receptor and janus kinase 2 are decreased *(216)*. Future studies should address the question of carcinogenicity in mice with AhR overexpressing and null alleles on different mouse strain backgrounds. In the human, exposure to TCDD has been associated, but not causally linked to an increased cancer risk *(217, 218)*. In part, the human AhR receptor is less sensitive to activation by AhR ligands *(196)* and in part, the exposure level in humans has been below that required to cause sustained tumor promotion *(219)*. Other agents in the class including certain polychlorinated biphenyls and the tetrachlorofurans may act in part through an AhR-dependent mechanism. Each agent has a unique contribution of AhR, CAR, and ER-dependent activity as well as other actions including cytotoxicity that may contribute to its carcinogenicity in rodents and provide a potential risk to the human. Certain exposures to mixtures of PCBs and furans have been associated with an increased risk of human liver disease and cirrhosis *(220)*, but a causal link has not been made to cancer. Even in worker populations, the low incidence and lack of consistent dose trend prohibits the conclusion of causality *(221)*. The risks at high dose exposure differ from the risks posed by ambient exposures and should not be oversimplified.

3.2.5. ETHIONINE

Ethionine, an antimetabolite of the amino acid methionine, when administered in the diet for extended periods can result in the development of liver cancer in rats *(29)*. This was the first example of direct interference with the metabolism of a normal metabolic constituent, resulting in the development of cancer. Ethionine induces marked steatosis that progresses to NASH, cirrhosis, and HCC *(30, 222)*. Its ability to disturb one-carbon pools (rats are ten times more sensitive than humans to choline deficiency), folate metabolism, and to induce steatosis is similar to alcohol-induced changes that progress to cirrhosis and ultimately to HCC. This compound interferes with methylation causing hypomethylation upon chronic administration *(223)*. This agent is not used in the human.

4. PATHOGENESIS OF HCC

The pathogenesis of human HCC has been examined extensively *(6–8, 81)*. Generally, the neoplasms are detected at late stage when many concurrent genetic changes are apparent. Tracing the earliest genetic changes in clinical samples has been limited. Studies using CGH arrays and gene expression analysis indicate that multiple pathways and multiple mechanisms lead to HCC development and progression due in part to different etiologies and time during pathogenesis of clinical detection. Primary liver cancer associated with cirrhosis evolves from precancerous lesions. Dysplastic nodules have variable degrees of atypia and can exhibit a focus or nodule in nodule appearance that can range from normal appearing to neoplastic in appearance. The formation of dysplastic nodules is not required for HCC development. Large cell dysplasia appears to be a response to injury and is not strictly a preneoplastic lesion although it is associated with an increased risk of HCC in a cirrhosis background of more than 3-fold *(6)*. On the other hand, small cell dysplasia seems more characteristic of preneoplastic change with greater than a 6-fold risk *(6)*. These small cell dysplastic cells are more diploid and less differentiated in character than the large cell dysplasias.

4.1. Rodent Models of Hepatocarcinogenesis

Examination of the epidemiology of liver cancer in humans indicates that both genetic and environmental factors are involved in the etiology and evolution of this disease. Studies in rodents can provide insight into the various factors involved in liver carcinogenesis. Early studies on rodents exposed to carcinogens indicated that male rodents are more likely to develop liver tumors *(224, 225)*. Rats, although relatively resistant to the spontaneous induction of liver neoplasms, will develop hepatic tumors later in life with

a sex-bias in incidence that differs between strain and study *(226)*. This compilation of strain background effects on spontaneous liver tumors in rats suggests that females have a slightly higher rate in Charles River CD, Osborne–Mendel, and Fischer rats and the incidence in males being marginally greater in the Wistar strain. Hepatic tumors can be readily induced in the rat by a variety of carcinogenic agents, with the male generally more sensitive than the female. The cancer bioassay is performed in two species of rodent, the rat and mouse. The sex specificity of liver tumor induction is, however, carcinogen specific due in large part to the sex dependence of the metabolic pathways.

4.2. Rat Models

The rat liver has been used extensively as a model of the carcinogenic process *(5, 17)*. Three basic protocols with numerous variations have been described including resistant hepatocyte model, neonatal rat model, and the partial hepatectomy model. These models couple carcinogen administration with a period of rapid cell proliferation due to the intrinsic growth of the tissue in the neonate, the wave of proliferation that occurs following surgical resection, or the extensive necrosis induced by excessive carcinogen administration. These studies can be used to examine very early changes in the pathogenesis of preneoplasia in the rat liver. The initiation–promotion–progression (IPI) model *(227)*, the Solt–Farber model *(228)*, and transgenic *(229)* rat models can be used to analyze later focal hepatic lesions, adenomas, and carcinomas. The utility of the rodent as a model lies in the ability to assess the changes associated with early premalignant changes that would not be detected in clinical samples that present late in the progression process. In addition, rodents can be used to model gene–environment interactions in a controlled manner. Thus, the early premalignant changes, as well as the initial stages and pathways in progression of primary liver cancer are tractable in rodent models, while human cases are more amenable to analysis of later progression.

The rat has been used extensively as a model to examine the process of liver cancer development and to ascertain which compounds can influence cancer development in the liver. Studies by Bannasch *(230)* indicate that two pathways that evolve toward HCC in the rat are thyroid mimetic and insulin mimetic (insulin-signaling pathway) with resulting glycogen accumulation phenotype. With progression, a shift from anabolic to catabolic glucose utilization occurs in the insulin-dependent signaling pathway. Similarly in humans, diabetes mellitus predisposes to HCC development as an independent risk factor *(15)*. This effect is observed in livers of rats treated with phenobarbital and related types of agents that promote eosinophilic lesions, while a thyroid-like effect is observed for the basophilic lesions that

arise with PPARα agonist administration. Although PGST has been used as a marker of putatively preneoplastic lesions in the rat and is increased in expression in single cells following carcinogen exposure, in focal lesions with promotion, and in some neoplastic nodules and neoplasms, a deficiency of glucose-6-phosphatase expression may be more representative of hepatic lesions that will progress to neoplasia.

Analysis of the gene expression changes across the carcinogenesis process and especially in preneoplastic lesions or following carcinogen exposure can illuminate the processes impacted by carcinogens. Recently, gene expression analysis has been applied to gain a clearer understanding of the changes that accompany liver cancer development in the rat. Many of these studies have been performed using variations on the Solt–Farber selection model for rat liver cancer induction *(228)*. Preneoplastic lesions have a higher level of expression of genes that are anti-apoptotic (p53, NK-kB, and Bcl-2 pathways) and pro-proliferation *(231)*. Proliferation gene changes are also common in liver tumors, while apoptosis was decreased *(232, 233)*. Early nodules demonstrate a decrease in both growth hormone receptor and growth hormone binding proteins *(234)*. Specifically, IGF2 is expressed during liver cancer development, while IGF1 is decreased during liver cancer development *(235)*. These more fetal-like gene expression patterns are observed during early tumor development *(236)*. The increased expression of TGFα and HGF and their respective receptors, EGFR and met, observed in early nodules is lost with neoplastic progression *(237)*. Gene expression analysis demonstrates many genes in common between neoplastic nodules and HCC with only a few genes uniquely observed in HCC *(231, 237)*.

4.2.1. MULTISTAGE NATURE OF CANCER DEVELOPMENT

Molecular analysis of the pathogenesis of the natural history of liver cancer induction and progression has been extensively examined in the rodent. In the rat, single hepatocytes aberrantly expressing glutathione-*S*-transferase P (GSTP) can be observed within 2 days of carcinogen exposure *(238–243)*. Under many conditions, GST expression has been suggested to represent a population of initiated hepatocytes in the rat liver *(240, 241, 243)*. This is true for several types of genotoxic carcinogens including diethylnitrosamine *(238, 243)*, an alkylating agent, aflatoxin B1 *(238)* that results in the formation of bulky DNA adducts, and choline-deficient diet that results in depletion of methyl pools *(242)*. Single GSTP-expressing hepatocytes are found in a dose-dependent manner following carcinogen administration *(238)*. Some subset of these cells will grow into colonies of hepatocytes also expressing GSTP. These findings suggest that the single GSTP-expressing cells are precursors of those that form colonies and by definition of some of those that will progress into hepatic neoplastic nodules and HCC. Single hepatocytes expressing GST have the characteristics associated with

initiated liver cells; namely, dose-dependent induction with carcinogen administration, rapid appearance after carcinogen treatment, enhanced intrinsic proliferation compared with surrounding apparently normal hepatocytes, and response to the selective growth pressure exerted by a promoting agent *(238)*. Expression of genes at the single cell level has been inadequately characterized, but GSTP and GGT are increased in certain hepatocytes following carcinogen administration.

4.2.2. PROMOTION

The promotion stage of cancer development has been operationally defined as the clonal expansion of the initiated cell population. The growth kinetics of GST-expressing hepatocytes can be followed over time through the analysis of the size and volume fraction of the liver occupied by GST-expressing hepatocytes *(238)*. The hepatocytes within AHF during promotion are primarily diploid *(244, 245)* and additionally lack demonstrable karyotypic changes *(245)*. Promoting agents stimulate the growth of the focal hepatocytes in a reversible manner and this can be determined by assessment of the size of the observed (GST expressing) hepatic lesions and by determination of focal increase in the expression of cell proliferation markers *(246)*. The net growth rate of GST-expressing hepatocyte colonies can be determined from the volume fraction occupied by such lesions as a function of time. The net growth rate thus reflects the balance between the birth and death rate within this population in relation to that observed in the surrounding apparently normal cells. While many of the GSTP-expressing lesions will regress, the nodules that concurrently express GSTP and gamma-glutamyltranspeptidase (GGT) appear to be the ones that progress. The loss of expression of glucose-6-phosphatase has also been associated with progression, but it is unclear whether this is through a different mechanism than for GSTP-expressing lesions. Gene expression has been examined in these early putatively preneoplastic lesions that precede nodule in nodule of HCC.

4.2.3. PROGRESSION

The stage of progression encompasses the spectrum of changes that occur in the conversion of preneoplastic cells into malignant neoplasia *(247)*. There is not as yet a validated method for the quantitation of hepatocytes in the stage of progression. This stage is characterized by an evolving karyotypic instability and aneuploidy indicating the necessity of understanding alternative pathways in progression of liver neoplasia. Morphologically, the focus in nodule configuration is the earliest endpoint for detection of progression in the liver *(227, 248, 249)*.

4.3. Mouse Models

Certain mouse strains are more susceptible to spontaneous *(224)* and chemically induced *(250)* hepatic tumors than other strains. An upregulation of c-jun may mark single altered cells in the mouse liver *(251)* analogous to the increased GSTP expression in the rat. The focal areas of change can be detected in frozen sections by the loss of expression of glucose-6-phosphatase. Alternatively, H&E stained sections demonstrate the presence of two distinct lesion types (A and B). Discussions by Schwartz indicate that one class contains Ha-ras mutations, while the other class contains β-catenin mutations. The C57Bl/6 (resistant) and the C3H (sensitive) strains differ in their susceptibility to spontaneous and chemically induced liver cancer development *(252)*. The hepatocarcinogenesis susceptibility allele (Hcs) is autosomal and is inherited in a semi-dominant manner with the F1 between the sensitive and resistant strain demonstrating an intermediate phenotype. This phenotype is believed to be cell autonomous factor *(253)*. In a study performed by Drinkwater et al. *(254)*, BXH (RI strains developed from a cross between C57Bl/6 (B) and C3H (H) mice were subjected to neonatal ENU administration. BXH strains 6, 14, and 10 were resistant, while BXH strains 8, 9, 7, and 3 were sensitive to ENU-induced increases in liver tumor multiplicity. A number of susceptibility gene loci have been described genetically for mouse liver cancer development. These cancer modifier loci have been mapped to specific chromosomal locations based on the Mendelian inheritance patterns in inbred mouse strains that are sensitive and resistant to cancer development *(255)*. Strain differences in sensitivity to liver cancer development were described by Andervont *(255a)* indicating a genetic component to the spontaneous development of liver cancer in mice. A few of these genes have been identified by positional cloning approaches. In addition, human homologues of cancer sensitivity and resistance alleles have been proposed. The C3H strain is susceptible to spontaneous and carcinogen-induced liver cancer development, while the C57/Bl6 mouse is by comparison resistant. The hepatocarcinogenesis sensitivity (HCS) and resistance (HRS) alleles have been defined for the mouse. A hepatic susceptibility locus on mouse chromosome 1 accounts for 85% of the variance between these two mouse strains *(252, 256)*. Studies with other mouse strains and other carcinogens have also been performed *(157)*.

The National Toxicology Program assesses cancer risk in the C3B6 F1 mouse that carries the dominant susceptibility allele for liver cancer development. The most common experimental cancer assessment tool is the neonatal mouse model *(257)* as first described by Vesselinovitch *(258)*. Numerous models of human liver diseases exist. Many of these are developed as a complicated toxin or carcinogen regimen *(17)*. In addition, genetically modified mice have been made against signaling pathway members

believed important in liver cancer development *(229)*. These rarely are a complete recapitulation of the human disease, but are nonetheless useful for modeling one component of the disease. The challenge is to couple etiologic agents, with pathway perturbations and disease models to unravel components of the pathogenesis of human primary liver cancer *(17, 229, 259)*.

Analysis of early and progressive lesions that arise in the mouse, rat, and human will provide a mechanism by which to develop models of human liver cancer development, pathogenesis, and progression.

5. ETIOLOGY IN THE HUMAN

Patients at risk for HCC include those with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection *(260)*, certain metabolic liver diseases, such as hereditary hemochromatosis *(261)*, Wilson's disease, alpha-1 antitrypsin deficiency, and porphyria cutanea tarda *(7, 8)*. Individuals with cirrhosis are at risk of HCC *(7, 262)*. Heavy alcohol consumption is also a common major risk factor for developing HCC *(7, 8, 83, 85, 262)*. Other predisposing factors include gender (males are times more likely to develop HCC than females), smoking, and diabetes *(262)*. Environmental influences, including carcinogen exposure and viral hepatitis prevalence, are believed to contribute to its distinct geographical distribution pattern *(8)*. Specifically, chronic infection with HBV and exposure to aflatoxin in the diet contribute to high-risk levels of HCC *(263)*. Thus, primary liver cancer is a product of environmental exposures with genetic consequences. In the United States, the largest cross-sectional study of HCC identified infection with HCV and/or HBV as the most common risk factor for HCC (47% HCV, 15% HBV, 5% both). Approximately, 33% of primary liver cancer in the United States are not associated with HBV or HCV *(8)*. The incidence of HCC is increasing in the United States primarily due to an increase in hepatitis C virus infection *(8)*.

5.1. Cirrhosis

Individuals with cirrhosis, regardless of its etiology are at risk for HCC *(7, 262)*. Fibrosis of the liver can result as a response to liver injury or as a component of selected genetic diseases *(264, 265)*. Cirrhosis is the end stage of fibrotic disease. Cirrhosis of the liver can occur during the progression of alcoholic hepatitis, non-alcoholic steatohepatitis (NASH), viral hepatitis, and cholestatic liver diseases *(266)*. Viral hepatitis (HBV and HCV) and alcohol are the primary causal factors in liver cirrhosis, while NASH, certain genetic diseases (e.g., hemochromatosis), and immune-mediated

damage provide other contributing factors *(7, 8)*. There is an increased risk of primary liver cancer in individuals with hepatitis C-associated cirrhosis and diabetes mellitus *(267)*. In some conditions, cirrhosis can progress to hepatocellular carcinoma.

5.2. Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of elevated serum enzymes indicative of liver injury and may be due to many etiologies *(268–270)*. An independent diagnostic test or disease marker is not available for NAFLD. The NAFLD disease continuum, which has a worldwide prevalence of 20%, is defined to exclude viral hepatitis, autoimmune diseases, metabolic changes due to hemochromatosis, alpha-1 antitrypsin, and ceruloplasmin changes, and alcoholic liver disease despite the similarities of disease presentation. Steatosis appears to be a benign condition, but steatohepatitis is progressive *(268–270)*. Essentially all morbidly obese individuals have NAFLD and approximately 25–50% exhibit steatohepatitis. For non-alcoholic steatohepatitis (NASH) patients (prevalence of 1–5% in the general population) approximately 20% will progress to cirrhosis, with a small percentage of these progressing to hepatocellular carcinoma. Approximately 10% of individuals with NASH will die of liver-related diseases *(269)*. NASH is common in type 2 diabetes and has a prevalence of 60% *(269–271)*. Morbid obesity is another risk factor for NASH. Approximately, 2–3% of lean individuals exhibit NASH, while 15–20% of obese individuals have steatohepatitis at non-liver initiated autopsies. Individuals that have insulin resistance are susceptible to the development of steatosis (fatty liver) and its progression to non-alcoholic steatohepatitis (NASH). In some individuals, steatohepatitis can progress to cirrhosis and in a limited number of cases can progress to primary liver cancer *(271)*. Recently animal models of NAFLD and NASH have been developed, but these do not completely recapitulate the pathogenesis of the related diseases and do not progress to cirrhosis or HCC without additional provocation *(272)*. Current trends suggest that the NAFLD continuum is not as benign as once thought and that progression to NASH, cirrhosis, and potentially HCC can occur depending on the interaction of genetic, environmental factors, and underlying disease including diabetes, HFE, among others *(273–276)*.

5.3. Viral Hepatitis

Chronic infection with HBV or HCV is the predominant risk factor for development of HCC, accounting for up to 80% of liver cancer cases in geographic regions of high incidence of the disease *(7, 8, 277)*. Although much of the HCC incidence is attributable to chronic HBV infection, only a

low percentage of individuals that are infected with HBV go on to develop progressive liver disease even though 80% or more develop chronic infection. Approximately one third of individuals with chronic infection will develop cirrhosis and HCC develops in less than 5% of those that develop cirrhosis *(278)*. Carriers of HBV have 100-fold risk of developing HBV *(277)* that has been suggested to be closer to 5–15-fold in case–control studies with a lifetime risk of 10–25%. The annual incidence in HBV carriers is less than 1% *(279)*. It increases to greater than 1% in those with hepatitis and to 2–3% in those with cirrhosis. Although rates of infection with the viruses are similar in men and women, there is some evidence that progression of the disease is more likely to occur in men *(7)*. Among chronic carriers of hepatitis B surface antigen (HBsAg) in Taiwan, the ratio of men to women was 1.2 for asymptomatic individuals, but there were six times as many men as women among patients with chronic liver disease *(278)* in concert with the greater prevalence of chronic hepatitis and cirrhosis in men *(278)*. A prospective study of liver cancer development among men in Taiwan has indicated a relationship between serum testosterone levels and risk for HCC *(278–281)*. Men, whose testosterone levels were in the highest tertile (>5.7 ng/ml), had a relative risk of 2 for development of HCC when compared with men having lower testosterone levels *(280)*. When other risk factors, including HBsAg carrier status, anti-HCV positivity, and alcohol consumption, were taken into account, the relative risk for men with high testosterone levels was 4 *(279, 281)*. However, this difference may have been due to a higher proportion of HBsAg carriers among the liver cancer cases. In developed countries, HCV infection is a more prevalent risk factor for HCC. HCV infection results in a 15-fold increase in risk of HCC compared with uninfected individuals. Approximately, 90% of HCV carriers develop hepatitis, while 20% of HCV carriers develop cirrhosis. Cirrhotic HCV patients develop HCC at a rate of 1–4% per year *(7, 8, 279, 281)*. The high rate of cirrhosis development results in a risk of HCC over the lifetime of 1–3%. The risk of HCC is further increased in HCV carriers for alcohol excess and HFE carriers *(279, 281)*.

5.4. Aflatoxin and Other Dietary Carcinogens

A number of dietary factors have been associated with HCC risk including exposure to aflatoxin (a fungal product of *Aspergillus flavus* and related species). The risk of HCC is exposure (dose and duration) dependent *(26, 282)*. The risk is heightened in those with HBV *(283)*. This toxic substance is produced by certain strains of the mold *Aspergillus flavus*. Aflatoxin B_1 is one of the most potent hepatocarcinogenic agent known and has produced neoplasms in rodents and primates *(26)*. This agent is a potential contaminant of many farm products (the common food staples, grain, and peanuts)

that are stored under warm and humid conditions for some time. Aflatoxin B_1 and related compounds may cause some of the toxic hepatitis and hepatic neoplasia seen in various parts of Africa and the Far East *(284)*. Thus, an important environmental and experimental hepatocarcinogenic agent is aflatoxin B_1. Other products of molds and fungi are potentially carcinogenic in humans and animals including fumonisins *(285)*. Other fungal *(286, 287)* and microbial products *(288)* may similarly be associated with HCC risk. Certain alkaloids are cytotoxic to the liver and may be associated with an increased risk of liver cancer. A number of plants, some of which are edible, also contain chemical carcinogenic agents whose structures have been elucidated *(289)*. These include the pyrrolizidine alkaloids which are found in comfrey and riddelline *(290)*. The use of Senecio, Crotalaria, Heliotropium, and Symphytum species can result in veno-occlusive disorder. Acute toxicity can occur with high dose exposure, but lower doses and longer durations of treatment can result in chronic disease. While these agents are used as teas and herbal remedies, they have been associated with acute toxicity and when there is a genotoxic metabolite in addition to cytotoxicity the combination of DNA adduct formation and cell proliferation permits mutation induction and fixation. Similarly, a low intake of retinoids, selenium, vitamin E and other antioxidants may also be associated with an increased risk when combined with other risk factors *(291–295)*.

5.5. Alcohol and Tobacco

Alcohol abuse has been associated with HCC development that occurs in a background of hepatitis and cirrhosis *(81, 262)*. Alcohol abuse can potentiate HCV and HBV to increase the incidence of HCC *(87)*. This incidence is markedly increased in individuals with high AFP levels, high cell proliferation index, and in uncompensated patients with atypical macroregenerative nodules. In those with compensated liver fibrosis, the risk of HCC is 3% *(87, 296, 297)*. Both case–control and prospective studies have indicated that excessive alcohol consumption increases the risk of liver cancer development by up to 3-fold, a result likely due to the induction of liver cirrhosis *(296, 298, 299)*. Liver cirrhosis due to excessive alcohol intake is an important risk factor in countries with a low incidence of HCC. Since chronic alcohol abuse is more prevalent among men than women, this risk factor may also contribute to the higher incidence of HCC in men than women *(300)*. Alcohol abuse may be an independent risk factor for HCC in areas of endemic HBV or HCV infection with an attributable risk of approximately 20% in one study *(299)*. Alternatively, associations between gender and lifestyle-associated risk factors, including smoking and alcohol consumption, have been suggested as potential determinants of the sex difference in HCC risk resulting in a male bias in the prevalence of this disease. There

is a positive impact of cigarette smoking on HCC risk *(301–307)*. However, higher rates of HCC are observed in heavy smokers when all other risk factors were taken into account *(307)*. Thus, the lifestyle factors of smoking and alcohol intake contribute to the induction and progression of HCC in a dose dependent and synergistic manner in both high- and low-risk geographical areas *(304, 305)*. Alcohol abuse can increase the risk of HCC in hepatitis virus carriers by at least 2-fold *(87)*.

5.6. Steroids

The factors underlying the sex difference in human risk of developing liver cancer have not been determined. However, the geographical and ethnic diversity in the populations at risk indicate that sex hormone-related factors may underlie the higher incidence of liver cancer development in men. Similarly elevated levels of testosterone result in an increased incidence of hepatic adenomas *(308)*. In men taking anabolic steroids, an increased incidence of liver adenomas has also been observed *(309–311)* and these lesions may or may not regress upon cessation of androgen therapy *(312–313)*. Oxymetholone, methyltestosterone, and danazol administration were associated with hepatic neoplasms in certain cases. HCC was associated with oxymetholone and methyltestosterone in some patients, while adenomas were associated with danazol exposure *(311)*. These studies support the potential for elevated testosterone levels to contribute to the development of hepatocellular carcinoma development *(263, 278)*. Significant associations have been observed between polymorphisms in three hormone-related genes and HCC. These include androgen receptor, 5-alpha reductase, and cytochrome P450 17 alpha *(263)*.

Exposure to either anabolic steroids or certain oral contraceptive formulations has been associated with the increased incidence of hepatic adenomas and in rare instances with HCC development in humans. The earliest report of an association between liver cancer induction and exposure to exogenous sex hormones described seven cases of benign hepatomas in young women with a history of oral contraceptive use *(314)*. Women of child-bearing age appear to be sensitive to the induction of benign hepatic adenomas and the induction of these liver tumors is enhanced by exposure to oral contraceptives. These tumors respond to hormonal manipulations such that they regress upon cessation of hormonal administration *(145)* and grow or progress upon continued administration of these agents. While a dose (estrogenic potency) and duration effect is seen for oral contraceptive use and adenoma development, the association with carcinoma induction is very low and only detectable with greater than 8 years of exposure *(315)*. Several investigators reported that the relative risk for adenoma development increased sharply beyond 5 years of oral contraceptive

use *(316, 317)*. While formulations containing mestranol and ethinyl estradiol have led to equivalent risks, the incidence of liver cancer among women using high potency oral contraceptives was significantly greater than that for users of low-potency formulations. Oral contraceptive use has also resulted in an increased risk for malignant liver cancer *(318)*. Case–control studies in the United States, Britain, and Italy demonstrated a 5-fold increased risk for hepatocellular carcinoma among women with more than 5 years use of oral contraceptives relative to women with exposures of shorter duration *(315, 318–320)*. In contrast, estrogen replacement therapy does not increase the risk for hepatocellular carcinomas *(315)*. Thus, excess exposure to hormonally active agents can increase the risk of HCC.

5.7. *Genetic Disorders*

A number of metabolic diseases have been associated with an increased risk of HCC *(7, 8)*. These include hemochromatosis, tyrosinemia, citrullinemia, porphyrias, and alpha-1 antitrypsin. Individuals with cirrhosis and genetic hemochromatosis have a markedly increased rate and shortened time until HCC development that is exacerbated by viral infection and alcohol abuse *(263, 278)*. Other metabolic diseases can increase the risk of HCC but to a lesser degree. These include Wilson's disease, fructose intolerance, and type I and III glycogen storage disease. Thus, the variety of the underlying disease base that contributes to HCC demonstrates the multifactorial risk profile for primary liver cancer development.

5.7.1. Metal Overload Disorders

Iron overload *(260, 321)* has been associated with hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Hereditary disturbances in iron uptake *(322–324)* and metabolism result in one form of iron overload and dietary ingestion excess *(325)* a second. A variety of iron overload conditions have been associated with HCC even in the absence of cirrhosis including sideroblastic anemia and thalassemia *(321, 326)*. In certain areas of sub-Saharan Africa, the natives ingest drinks with concentrated iron. These individuals have an increased incidence of both cirrhosis and HCC *(325)*. Porphyrias occur due to defects in the heme biosynthetic pathway. Both acute intermittent porphyria and porphyria cutanea tarda have been associated with an increased risk of HCC *(324)*. The mechanism is unknown, but the presence of free iron in the tissue may be a contributory factor. In combination with HBV infection, HCV infection, alcohol cirrhosis, iron overload induced an increase in lipid peroxidation and the rate of progression to steatohepatitis, cirrhosis, and HCC *(86, 262)*. Underlying liver

disease including cholestasis, steatosis, and cirrhosis can impact the degree and latency to disease onset and progression with iron overload syndromes.

Hereditary hemochromatosis was first described as a hereditary disease associated with HLA linkage and a form of pigment-associated cirrhosis typically associated with diabetes. A prevalent gene mutation *(323)* was found to underlie hereditary hemochromatosis (HFE) and a knock-out mouse *(327)*. Although several genetic factors can be involved in iron overload, the most common is in HFE (85–90%). Although several polymorphisms exist, the most prevalent is C282Y (85–100% attribution to HFE). The prevalence is 1 in 250 with an allelic frequency of 5%. The second polymorphism allele that is common in HFE is H63D. Carriers of this allele comprise 15–20% of the American population, but the consequence of this allele is not known *(323)*. The HFE is an MHC class 1 molecule that is associated with β2 microglobulin (B2M) and the major polymorphism C282Y prohibits this interaction. Studies in a B2M knock-out mouse demonstrate an iron overload syndrome *(328)*. In the HFE knock-out mouse, periportal iron deposition occurs in conjunction with elevated transferrin saturation *(327)*. Interestingly, HFE and B2M which are in a complex with transferrin receptor result in an increase in intestinal iron absorption. HFE mutation carriers cannot facilitate iron uptake by transferrin receptor *(329, 330)*. Transferrin receptor Ser142 alleles are increased in liver cancer cases and in addition, TfR expression is increased in hepatic preneoplasia and in HCC *(330)*. The odds ratio for C282Y allele carriers with TFR142Ser alleles for HCC is 17.2, while it is 62.8 in those with cirrhosis for HCC development demonstrating the contribution of TfR to risk of HCC *(330)*.

The long-term consequences of iron overload on the liver include fibrosis and cirrhosis that can be exacerbated by the presence of underlying liver disease *(260, 321)*. The incidence of HCC in hereditary hemochromatosis (HH) is increased over 100× relative to a comparative control population *(260, 331)*. Outcomes in heterozygotes for HFE seem similar to wildtype, except for those 1–2% individuals who are compound heterozygotes with C263Y/H63D *(332, 333)*. The odds ratio of HCC in HFE C282Y carriers or homozygotes is 3.5, while it is 7 in those with cirrhosis indicating that HFE is a risk factor for HCC *(333)*. The HCC population is enriched for C282Y carriers than is found in the general population indicating a possible risk factor for its development and progression *(332–334)*. The increased risk from HFE alleles is found in alcoholic cirrhosis and some cases of HCV viral hepatitis, but not HBV viral hepatitis patients *(322, 332, 334)*. Animal models of liver disease in combination with iron overload also demonstrate an increase in disease progression. For example, transgenic mice overexpressing the HCV polyprotein fed a diet enriched in iron develop microvesicular steatosis indicative of mitochondrial damage and impaired energy use with fatty acid retention and earlier onset of HCC than their

littermates similar to those humans that develop fatty liver with HCV infection *(335)*. A wide range of hepatic tumor phenotypes is observed in HFE *(336)*. Interestingly, a high incidence of p53 mutations has been observed in one series of HCC from HFE patients *(337)*. Importantly, epigenetic defects are observed in liver tissue from 75% of the HFE patients examined prior to the onset of cirrhosis with hypermethylation and hence gene expression decreases *(338)*.

Wilson's disease or inherited copper overload disease can result in cirrhosis, hepatitis, and HCC. Wilson's disease is found in 1:30,000 with a carrier rate of 1:250 *(339)*. Cerruloplasmin is decreased in the serum of Wilson's disease patients. This autosomal recessive disorder is due to a mutation in the P-type ATPase responsible for biliary copper excretion (ATP7B) located in the trans-Golgi network *(340)*. The most prevalent mutation, H1069Q, is observed in 30% of Wilson's patients of European decent. Other mutations of the ATP7B gene exist and can also result in Wilson's disease *(339)*. In addition, modifier genes that impact the severity of the disease also exist. Copper is normally ingested and absorbed through the GI tract and excreted through the bile. Copper is transported in the serum bound to histidine. Copper binds to glutathione or metallothionein, and cerruloplasmin. It is excreted into the bile in part through a secretory pathway involving ATP7B. The Long Evans Cinnamon rat is susceptible to non-viral hepatitis with subsequent formation of liver neoplasms, the male is more susceptible to the development of liver tumors *(341, 342)*. The LEC rat is a model of Wilson's disease that develops a non-viral hepatitis due to copper overload. These rats also have disturbances in iron metabolism. Those animals that survive the hepatitis will develop HCC. The toxic milk mouse has a mutation in M1356V and G712D, has defects in copper transport *(343)*, and a knock-out mouse (ATP7B) has also been generated *(344)*. If intracellular copper accumulates beyond the ability of the hepatocyte to buffer it, then hepatic damage will ensue with copper release into the circulation and its accumulation in other tissues.

5.7.2. ALPHA-1 ANTITRYPSIN

Alpha-1 antitrypsin (AAT) is a prevalent protease inhibitor (Pi) found in the plasma *(345)*. The most prevalent mutation is a Glu342Lys caused by a G to A transition called the Z mutation *(346, 347)*. Adult males that are homozygous for the Z mutation (PiZZ) have an increased risk of cirrhosis and HCC *(346–348)*. Alpha-1 antitrypsin results in an increased risk of HCC in the absence of cirrhosis in homozygotes *(348)*. Carriers (PiZ) are also believed to be at an increased risk for HCC *(349)* especially in combination with other risk factors *(350, 351)*. While the mechanism of α1AT alleles on disease etiology is unclear, the altered protein structure may

induce the unfolded protein response. Alternatively, this acute phase serum protein, which acts as an inhibitor of elastase and is synthesized by the liver and macrophage is retained in the liver resulting in a plasma insufficiency. Retention in the liver and consequent polymerization can result in cirrhosis and to HCC *(346, 347)*.

5.7.3. HEREDITARY TYROSINEMIA

Tyrosinemia is an autosomal recessive disorder that can lead to HCC. This inborn error of metabolism results *(352)* from inactivation of fumarylace-toacetate hydrolase (FAH) resulting in the buildup of its substrate fumary-lacetoacetate (FAA) and malylacetoacetate (MAA). As a consequence, these individuals excrete high levels of succinylacetone into the urine *(352)*. MAA and more specifically FAA have multiple effects on liver cells including apoptosis, ER stress response, redox balance including GSH depletion, and cell cycle arrest. Since the last step in the catabolism of tyrosine is blocked, tyrosine is elevated in the serum. These patients have a rapid conversion from micro to macronodular cirrhosis and later conversion to dysplasia and HCC. Without pharmacological (nitisinone) treatment or now surgical intervention, the prognosis was poor with acute liver failure predominant, followed by HCC *(353, 354)*. A mouse model has been developed in which FAH is knocked out *(355)*. This mutant recapitulates the pathogenesis of human hereditary tyrosinemia type 1 and can be protected by nitisinone *(356)*. Intervention with nitisinone does not reverse gene expression changes associated with tyrosinemia *(357)*. Thus, pharmacological treatment can delay, but may not prevent HCC development. Genetic manipulation reversal of double mutant FAH mice formed through ENU mutagenesis do not develop preneoplastic lesions or HCC, suggesting that the lack of complete reversal of the phenotype by pharmacological intervention is due to incomplete blockage of the formation of toxic intermediates *(358)*.

5.7.4. CITRULLINEMIA

The inborn errors of disease associated with the urea cycle *(359, 360)*; namely, mutation of arginosuccinate results in acute liver toxicity *(361)*. Citrullinemia type I is an autosomal recessive disorder that is caused by a deficiency in the rate-limiting enzyme in the urea cycle, argininosuccinate synthetase (ASS1). In severe cases, a hyperammonia can occur that is fatal neonatally. An argininosuccinic aciduria with an increase in citrulline and ammonia in the serum is observed. Since citrulline is essential in nitrogen homeostasis, disruption of ammonia removal results in toxicity to the liver. There is a broad mutational pattern and each genotype has different phenotypes *(361)*. A knock-out mouse has been generated that has high citrulline blood levels and a severe hyperammonemic phenotype *(362, 363)*. The aspartate–glutamate carrier (AGC), SLC25A13, gene

mutations result in citrin deficiency *(364)* and may develop hepatic steatosis and steatohepatitis *(365)*. These type 2 citrullinemia patients have an increased level of pancreas-derived trypsin inhibitor and are associated with pancreatitis *(364)*. A decrease in this mitochondrial ACG, citrin, results in hepatic apoptosis through a caspase pathway in which the bax to bcl2 ratio is inverted *(366)*. A knock-out model has been described, but does not recapitulate all of the pathologies associated with adult-onset type 2 citrullinemia *(367)*. The citrin/mitochondrial glycerol-3-phosphate dehydrogenase double knock-out mutant is a better model for type 2 citrullinemia *(368)*. Urea cycle disruption and perturbations of nitrogen removal can have adverse effects on the liver as exemplified by citrullinemia.

5.8. Summary

Chemicals from a variety of chemical classes can initiate, promote, and lead to the development or progression of HCC. The effects of chemical agents occur on the backgrounds of a variety of genetic alterations and diseases. Animal models have proven invaluable in the assessment of the early pathogenesis of primary liver cancer by chemicals. The late stage neoplasms analyzed from the human demonstrate that multiple etiologies, molecular pathways, and genetic changes accompany neoplastic development in the liver. Combinations of genetic factors, environmental exposures, and background liver disease will be modeled in increasing complex ways in the future to better recapitulate the role of chemicals in HCC development and progression. Systems biology tools as applied to the pathogenesis of HCC will be informative about the pathways that chemicals dysregulate in different genetic and disease backgrounds to lead to HCC development and progression.

REFERENCES

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2(9):533–43
2. www.cancer.org
3. Harris CC. Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol Biomarkers Prev 1994; 3(1):1–2.
4. Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol 2008; 26(17):2800–5.
5. Pitot H. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 1990; 30:465–500.
6. Rochen C, Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinomas. Dig Dis 2001; 19:269–78.
7. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19(1):3–23.
8. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132(7):2557–76.
9. GLOBOSCAN 2002

10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74–108.
11. Hussain SP, Harris CC. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res 2000; 462(2–3):311–22.
12. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(5 Suppl 1):S30–4.
13. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003; 36(1):47–53
14. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002 36(5 Suppl 1):S21–9.
15. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36(5):1206–13.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57–70.
17. Pitot HC. Animal models of neoplastic development. Dev Biol (Basel) 2001; 106:53–7.
18. Köhle C, Schwarz M, Bock KW. Promotion of hepatocarcinogenesis in humans and animal models. Arch Toxicol 2008; 82(9):623–31.
19. Sasaki T, Yoshida T. Experimentelle Erzeugung des Lebercarcinomas durch Futterung mit o-Aminoazotoloul. Virchows Arch Abt A Pathol Anat 1935; 295:175–200.
20. Kinoshita R. Researches on the cancerogenesis of the various chemical substances. Gann 1936; 30:423–26.
21. Heidelberger C. Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges. Cancer Res 1970; 30:1549–69.
22. Pullman A, Pullman B. Electronic structure and carcinogenic activity of aromatic molecules. New developments. Adv Cancer Res 1955; 38:117–69.
23. Miller J, Miller E. The carcinogenic amino azo dyes. Adv Cancer Res 1978; 1:339–96.
24. Miller E. Some current perspectives on chemical carcinogenesis in humans and experimental animals. Cancer Res 1978; 38:1479–96.
25. Preussmann R. Carcinogenic N-nitroso compounds and their environmental significance. Naturwissenscaften 1984; 71:25–30.
26. Dragan Y, Pitot H. Aflatoxin carcinogenesis in the context of the multistage nature of cancer In: The Toxicology of Aflatoxins: human health, veterinary and agricultural significance, New York: Academic Press, 1994:179–206.
27. Schoental R. Trichothecenes, zearalenone, and other carcinogenic metabolites of Fusarium and related microfungi. Adv Cancer Res 1985; 45:217–74.
28. Wiessler M. DNA adducts of pyrrolizidine alkaloids, nitroimidazoles and aristolochic acid. In: IARC Sci Publ., 125. Lyon, IARC, 1994:165–77.
29. Farber E. Ethionine carcinogenesis. Adv Cancer Res 1963; 7:383–474.
30. Mikol Y, Hoover K, Creasia D, Portier L. Hepatocarcinogenesis in rats fed methyl deficient amino acid defined diest. Carcinogenesis 1983; 4:1610–29.
31. Pitot HC. Adventures in hepatocarcinogenesis. Annu Rev Pathol 2007; 2:1–29.
32. Columbano A, Rajalakshmi S, Sarma D. Requirement of cell proliferation for the initiation of liver carcinogenesis. Cancer Res 1981; 41:2079–83.
33. Anderson M, Reynolds S, You M, Maronpot R (1992). Role of protooncogene activation in carcinogenesis. Environ Health Perspect 98:13–24.
34. Miller E, Miller J. The presence and significance of bound aminoazo dyes in the livers of rats fed *p*-dimethylaminoazobenzene. Cancer Res 1947; 7:468–80.
35. Weisburger E, Weisburger J. Chemistry, carcinogenicity, and metabolism of 2-fluorenamine and related compounds. Adv Cancer Res 1958; 5:331–431.
36. Miller J, Cramer J, Miller E. The N- and ring-hydroxylation of 2-acetylaminofluorene during carcinogenesis in the rat. Cancer Res 1960; 20:950–62.

37. Nagata C, Kodama M, Ioki Y, Kimura T. Free radicals produced from chemical carcinogens and their significance in carcinogenesis. In: Floyd R, ed., Free Radicals and Cancer, New York and Basel: Marcel Dekker, 1982:1–62.
38. Eling T, Thompson G, Foureman G et al. Prostaglandin H synthetase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990, 30:1–45.
39. Tennant R, Ashby J. Classification according to chemical structure, mutagenicity to Salmonella and level of carcinogenicity of a further 39 chemicals tested for carcinogenicity by the US National Toxicology Program. Mutat Res 1991; 257:209–27.
40. Ashby J, Paton D. The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 human carcinogen exposures. Mutat Res 1993; 287:3–74.
41. Friedberg E. Xeroderma pigmentosa, Cockayne's syndrome, helicases and DNA repair: what's the relationship? Cell 1992; 71:887–9.
42. Essigmann J, Wood M. The relationship between the chemical structures and mutagenic specificities of the DNA lesions formed by chemical and physical mutagens. Toxicol Letts 1993; 67:29–39.
43. Loeschler E. Adduct-induced base shifts: a mechanism by which the adducts of bulky carcinogens might induce mutations. Biopolymers 1989; 28:909–27.
44. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253(5015):49–53.
45. Singer B. O-alkyl pyrimidines in mutagenesis and carcinogensis: occurrence and significance. Cancer Res 1986; 46:4879–85.
46. Friedberg E. DNA repair: looking back and peering forward. Bioessays 1994; 16:645–9.
47. Vaino H, Coleman M, Wilbourn J. Carcinogenicity evaluations and ongoing studies: the IARC databases. Environ Health Perspect 1991; 96:5–9.
48. Pegg A, Perry W. Alkylation of nucleic acids and metabolism of small doses of dimethylnitrosamine in the rat. Cancer Res 1981; 41:3128–32.
49. Pegg A. Methylation of the O6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. Cancer Invest 1984; 2:223–31.
50. Swenberg J, Dyroff M, Bedell A et al. O4 ethyldeoxythymidine but not O6 ethyldeoxyguanosine accumulates in hepatocyte DNA of rats exposed continuously to diethylnitrosamine. Proc Natl Acad Sci 1984; 81:1692–5.
51. Shearman C, Loeb L. Effects of depurination on the fidelity of DNA synthesis. J Mol Biol 1979; 128:197–218.
52. Bichara M, Fuchs R. DNA binding and mutation spectra of the carcinogen N-2 aminofluorene in Escherichia coli: a correlation between the conformation of the premutagenic lesions and the mutation specificity. J Mol Biol 1985; 183:341–51.
53. Neumann H. Role of extent and persistence of DNA modifications in chemical carcinogenesis by aromatic amines. Recent Results Cancer Res 1983; 84:77–89.
54. Bishop J. Viral oncogenes. Cell 1985; 42:23–38.
55. Levine A. The tumor suppressor genes. Annu Rev Biochem 1993; 62:623–51.
56. Hunter T. Cooperation between oncogenes. Cell 1991; 64:249–70.
57. Nebert D. Role of genetics and drug metabolism in human cancer risk. Mutat Res 1991; 247:267–81.
58. Muller H. Recessively inherited deficiencies predisposing to cancer. Anticancer Res 1990; 10:513–8.
59. Hall A. A biological function for ras at last. Science 1994; 264:1413–4.
60. Rumsby P, Barrass N, Phillimore H, Evans J. Analysis of the Ha-ras oncogene in C3H/He mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone. Carcinogenesis 1991; 12:2331–6.

61. Kim Y, Sills R, Houle C. Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol Pathol 2005; 33:175–80.
62. Laurent-Puig L, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25:3778–86.
63. Marnett L, Burcham P. Endogenous DNA adducts: potential and paradox. Chemical Res Toxicol 1993; 6:771–85.
64. Shapairo R. Damage to DNA caused by hydrolysis. In Seeberg E, Kleepe K, eds., Chromosome damage and repair. New York, Plenum Press, 1981:3–18.
65. Floyd R. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 1990; 4:2587–97.
66. Srinivasan S, Glauert H. Formation of 5-hydroxymethyl-2'-deoxyuridine in hepatic DNA of rats treated with g-irradiation, diethylnitrosamine, 2-acetylaminofluorene, or the peroxisome proliferator ciprofibrate. Carcinogenesis 1990; 11:2021–4.
67. Ames B, Shigenaga M, Gold L. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 1993; 93:35–44.
68. Holliday R. A different kind of inheritance. Scientific American 1983; 260:60–73.
69. Michalowsky L, Jones P. DNA methylation and differentiation. Environ Health Perspect 1989; 80:189–97.
70. Riggs A, Jones P. 5-Methylcytosine, gene regulation and cancer. Adv Cancer Res 1983; 40:1–30.
71. Wilson M, Shivapurkar N, Poirier L. Hypomethylation of hepatic nuclear DNA in rats fed with a carcinogenic methyl-deficient diet. Biochem J 1984; 218:263–86.
72. Cohen S, Ellwein L. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 1991; 51:6493–505.
73. Hanawalt P. Transcription coupled repair and human disease. Science 1994; 266: 1957–8.
74. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266:1954–6.
75. Kaufmann W. Pathways of human cell post replication repair. Carcinogenesis 1989; 10:1–11.
76. Van Dyck E, Stasiak A, West S. Binding of double strand breaks in DNA by human Rad52protein. Nature 1999; 398:728–31.
77. Fishel R, Kolodner R. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995; 5:382–95.
78. Holsapple MP, Pitot HC, Cohen SM, Boobis AR, Klaunig JE, Pastoor T, Dellarco VL, Dragan YP. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 2006; 89(1):51–6.
79. Andersen ME, Meek ME, Boorman GA, Brusick DJ, Cohen SM, Dragan YP, Frederick CB, Goodman JI, Hard GC, O'Flaherty EJ, Robinson DE. Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds. Toxicol Sci 2000; 53(2):159–72.
80. Tan YM, Butterworth BE, Gargas ML, Conolly RB. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. Toxicol Sci 2003; 75(1):192–200.
81. McKillop I, Moran D, Jin X, Koniaris L. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136:125–35.
82. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Arch Surg 2006; 391:499–510.
83. Lieber C. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004; 34:9–19.

84. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7(2):149–56

85. Lieber C. Alcohol and hepatitis C. Alcohol Res Health 2001; 25:245–54.

86. Fletcher L, Dixon J, Pude D, Powell L. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122:281–9.

87. Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiology 2002; 155:323–31.

88. Boutwell, R. Function and mechanism of promoters of carcinogenesis. CRC Crit Rev Carcinogenesis 1974; 2:419–43.

89. Pitot H. The role of receptors in multistage carcinogenesis. Mutat Res 1995; 333:3–14.

90. [No authors listed] Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Human; Suppl. 7, Lyon, IARC Press, 1987:1–440.

91. Whysner J, Ross PM, Williams GM. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 1996; 71(1–2):153–91.

92. Weisburger JH, Madison RM, Ward JM, Viguera C, Weisburger EK. Modification of diethylnitrosamine liver carcinogenesis with phenobarbital but not with immunosuppression. J Natl Cancer Inst 1975; 54(5):1185–8.

93. Goldsworthy T, Campbell HA, Pitot HC. The natural history and dose-response characteristics of enzyme-altered foci in rat liver following phenobarbital and diethylnitrosamine administration. Carcinogenesis 1984; 5(1):67–71.

94. Peraino C, Fry RJ, Staffeldt E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res 1971; 31(10):1506–12.

95. Barbason H, Rassenfosse C, Betz EH. Promotion mechanism of phenobarbital and partial hepatectomy in DENA hepatocarcinogenesis cell kinetics effect. Br J Cancer 1983; 47(4):517–25.

96. Ward JM, Ohshima M. Evidence for lack of promotion of the growth of the common naturally occurring basophilic focal hepatocellular proliferative lesions in aged F344/NCr rats by phenobarbital. Carcinogenesis 1985; 6(9):1255–9.

97. Andersen ME, Mills JJ, Jirtle RL, Greenlee WF. Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Toxicology 1995; 102(1–2):223–37.

98. Dragan YP, Hully J, Crow R, Mass M, Pitot HC. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis 1994; 15(9):1939–47.

99. Kolaja KL, Stevenson DE, Walborg EF Jr, Klaunig JE. Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Carcinogenesis 1996; 17(5):947–54.

100. James NH, Roberts RA. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 1996; 17(8):1623–32.

101. Christensen JG, Gonzales AJ, Cattley RC, Goldsworthy TL. Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens. Cell Growth Differ 1998; 9(9):815–25.

102. Kinoshita A, Wanibuchi H, Morimura K, Wei M, Shen J, Imaoka S, Funae Y, Fukushima S. Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression. Carcinogenesis 2003; 24(8):1389–99.

103. Jirtle RL, Hankins GR, Reisenbichler H, Boyer IJ. Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carcinogenesis 1994; 15(8):1473–8.

104. Reisenbichler H, Chari RS, Boyer IJ, Jirtle RL. Transforming growth factor-beta receptors type I, II and III in phenobarbital-promoted rat liver tumors. Carcinogenesis 1994; 15(12):2763–7.

105. Mansbach JM, Mills JJ, Boyer IJ, De Souza AT, Hankins GR, Jirtle RL. Phenobarbital selectively promotes initiated cells with reduced TGF beta receptor levels. Carcinogenesis 1996; 17(1):171–4.

106. Jirtle RL, Meyer SA. Liver tumor promotion: effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-beta 1 expression. Dig Dis Sci 1991; 36(5):659–68.

107. Atchison M, Adesnik M. A cytochrome P-450 multigene family. Characterization of a gene activated by phenobarbital administration. J Biol Chem 1983; 258(18): 11285–11295

108. Pike SF, Shephard EA, Rabin BR, Phillips IR. Induction of cytochrome P-450 by phenobarbital is mediated at the level of transcription. Biochem Pharmacol 1985; 34(14):2489–2494.

109. Rice JM, Diwan BA, Hu H, Ward JM, Nims RW, Lubet RA. Enhancement of hepatocarcinogenesis and induction of specific cytochrome P450-dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl- and 5-ethylbarbituric acids. Carcinogenesis 1994; 15(2):395–402.

110. Kodama S, Negishi M. Phenobarbital confers its diverse effects by activating the orphan nuclear receptor car. Drug Metab Rev 2006; 38(1–2):75–87.

111. Forman BM, Tzameli I, Choi HS, Chen J, Simha D, Seol W, Evans RM, Moore DD. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998; 395(6702):612–5

112. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000; 407(6806):920–3.

113. Yoshinari K, Sueyoshi T, Moore R, Negishi M. Nuclear receptor CAR as a regulatory factor for the sexually dimorphic induction of CYB2B1 gene by phenobarbital in rat livers. Mol Pharmacol 2001; 59(2):278–84.

114. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 1999; 19(9):6318–22.

115. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62(3):638–46.

116. Ueda A, Hamadeh HK, Webb HK, Yamamoto Y, Sueyoshi T, Afshari CA, Lehmann JM, Negishi M. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002; 61(1):1–6.

117. Yamamoto Y, Moore R, Goldsworthy TL, Negishi M, Maronpot RR. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004; 64(20):7197–200.

118. Phillips JM, Yamamoto Y, Negishi M, Maronpot RR, Goodman JI. Orphan nuclear receptor constitutive active/androstane receptor-mediated alterations in DNA methylation during phenobarbital promotion of liver tumorigenesis. Toxicol Sci 2007; 96(1):72–82.

119. Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A, Schwarz M. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 1991; 88(3):911–5.

120. Aydinlik H, Nguyen T, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumor promotion by Phenobarbital leads to clonal outgrowth of β-catenin mutated mouse liver tumors. Oncogene 2001; 20:7812–16.

121. Stahl S, Ittrich C, Marx-Stoelting P, Köhle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, Schwarz M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 2005; 42(2):353–61.

122. Choi HS, Chung M, Tzameli I, Simha D, Lee YK, Seol W, Moore DD. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J Biol Chem 1997; 272(38):23565–71.

123. Wanless IR, Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest 1982; 46(3):313–20.

124. Taper HS. The effect of estradiol-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in ovariectomized female rats. Cancer 1978; 42(2):462–7.

125. Yager JD Jr, Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res1980; 40(10):3680–5.

126. Yager JD, Roebuck BD, Paluszcyk TL, Memoli VA. Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis 1986; 7(12):2007–14

127. Yager JD, Campbell HA, Longnecker DS, Roebuck BD, Benoit MC. Enhancement of hepatocarcinogenesis in female rats by ethinyl estradiol and mestranol but not estradiol. Cancer Res 1984; 44(9):3862–9.

128. Yager JD Jr. Oral contraceptive steroids as promoters or complete carcinogens for liver in female Sprague-Dawley rats. Environ Health Perspect 1983; 50:109–12.

129. Yager JD, Zurlo J, Sewall C, Lucier G, He H. Growth stimulation followed by growth inhibition in livers of female rats treated with ethinyl estradiol. Carcinogenesis 1994; 15:2117–23.

130. Dragan YP, Singh J, Pitot HC. Effect of the separate and combined administration of mestranol and phenobarbital on the development of altered hepatic foci expressing placental form of glutathione S-transferase in the rat. Carcinogenesis 1996; 17(9): 2043–52.

131. Chen J, Schwartz DA, Young TA, Norris JS, Yager JD. Identification of genes whose expression is altered during mitosuppression in livers of ethinyl estradiol-treated female rats. Carcinogenesis 1996; 17(12):2783–6.

132. Chen J, Gokhale M, Schofield B, Odwin S, Yager JD. Inhibition of TGF-beta-induced apoptosis by ethinyl estradiol in cultured, precision cut rat liver slices and hepatocytes. Carcinogenesis 2000; 21(6):1205–11.

133. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massagué J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science 1993; 260(5107):536–9.

134. Sánchez A, Alvarez AM, López Pedrosa JM, Roncero C, Benito M, Fabregat I. Apoptotic response to TGF-beta in fetal hepatocytes depends upon their state of differentiation. Exp Cell Res 1999; 252(2):281–91.

135. Houck KA, Michalopoulos GK, Strom SC. Introduction of a Ha-ras oncogene into rat liver epithelial cells and parenchymal hepatocytes confers resistance to the growth inhibitory effects of TGF-beta. Oncogene 1989; 4(1):19–25.

136. Kohigashi K, Fukuda Y, Imura H. Inhibitory effect of tamoxifen on diethylstilbestrol-promoted hepatic tumorigenesis in male rats and its possible mechanism of action. Jpn J Cancer Res 1988; 79(12):1335–9.

137. Mishkin S, Farber E, Ho R, Mulay S, Mishkin S. Evidence for the hormone dependency of transformation after exogenous 17β estradiol and tamoxifen. Hepatology 1983; 3:308–16.

138. Sumi C, Yokoro K, Matsushima R. Inhibitory effect of antiestrogen on hepatic tumorigenesis in WF rats treated with diethylstilbestrol alone and in combination with N-nitrosobutylurea. J Natl Cancer Inst 1984; 72:949–53.

139. [No authors listed]. Hormonal contraception and post-menopausal hormone therapy. In: IARC monographs on the evaluation of carcinogenic risk to humans. IARC, Lyon 1999; 69:49–565.

140. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36:203–32

141. Tsutsui T, Maizumi H, McLachlan JA, Barrett JC. Aneuploidy induction and cell transformation by diethylstilbestrol: a possible chromosomal mechanism in carcinogenesis. Cancer Res 1983; 43(8):3814–21.

142. Mayol X, Neal GE, Davies R, Romero A, Domingo J. Ethinyl estradiol-induced cell proliferation in rat liver. Involvement of specific populations of hepatocytes. Carcinogenesis 1992; 13(12):2381–8.

143. Dragan YP, Singh J, Pitot HC. Effect of the separate and combined administration of mestranol and phenobarbital on the development of altered hepatic foci expressing placental form of glutathione S-transferase in the rat. Carcinogenesis 1996; 17(9): 2043–52.

144. [No authors listed] Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Human; Suppl. 7, Lyon, IARC Press, 1987:1–440.

145. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86(2):180–2.

146. Pitot H, Goldsworthy T, Moran S et al. A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose response relationship to altered hepatic foci. Carcinogenesis 1987; 8:1491–9

147. Dragan Y, Pitot H. The instability of tumor promotion in relation to human cancer risk. In: McClain M, Slaga T, LeBouef R, Pitot H (eds.). Growth factors and tumor promotion: implications for risk assessment. Progress in Clinical and Biol Res V.391, New York, Wiley, 1995; 21–38.

148. Kitano M, Ichihara T, Matsuda T, Wanibuchi H, Tamano S, Hagiwara A, Imaoka S, Funae Y, Shirai T, Fukushima S. Presence of a threshold for promoting effects of phenobarbital on diethylnitrosamine-induced hepatic foci in the rat. Carcinogenesis 1998; 19(8):1475–80.

149. Dragan YP, Xu YD, Pitot HC. Tumor promotion as a target for estrogen/ antiestrogen effects in rat hepatocarcinogenesis. Prev Med 1991; 20(1):15–26.

150. White IN, De Matteis F, Gibbs AH, Lim CK, Wolf CR, Henderson C, Smith LL. Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 1995; 49(8):1035–42.

151. Epe B, Hegler J, Metzler M. Site-specific covalent binding of stilbene-type and steroidal estrogens to tubulin following metabolic activation in vitro. Carcinogenesis 1987; 8(9):1271–5.

152. Payré B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Tercé F, Fourquaux I, Goudounèche D, Record M, Poirot M, Silvente-Poirot S. Microsomal

antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther 2008; 7(12):3707–18.

153. de Médina P, Favre G, Poirot M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anticancer Agents 2004; 4(6):491–508

154. Yager JD, Shi YE. Synthetic estrogens and tamoxifen as promoters of hepatocarcino-genesis. Prev Med 1991; 20(1):27–37.

155. Gong Y, Zhang M, Minuk GY. Regulation of transforming growth factor-beta1 gene expression and cell proliferation in human hepatocellular carcinoma cells (PLC/PRF/5) by tamoxifen. J Lab Clin Med 1999; 134(1):90–5.

156. Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, Matthias P. Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J Biol Chem 2001; 276(38):35444–9.

157. Weiss DJ, Gurpide E. Non-genomic effects of estrogens and antiestrogens. J Steroid Biochem 1988; 31(4B):671–6.

158. Dragan YP, Shimel RJ, Bahnub N, Sattler G, Vaughan JR, Jordan VC, Pitot HC. Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats. Toxicol Sci 1998; 43(2):129–38.

159. Mayol X, Neal G, Davies R, Romero A, Domingo J. Ethinyl estradiol induced cell proliferation in rat liver. Involvement of specific cell populations of hepatocytes. Carcinogenesis 1992; 13:2381–8.

160. Carthew P, Martin EA, White IN, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 1995; 55(3):544–7.

161. Carthew P, Nolan BM, Edwards RE, Smith LL. The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett 1996; 106(2):163–9.

162. Kappus H, Bolt H, Remmer H. Demethylation of mestranol to ethylestradiol in vitro and in vivo. Acta Endocrinol 1972; 71:374–84.

163. Gindhart TD. Liver tumors and oral contraceptives: pathology and pathogenesis. Ann Clin Lab Sci 1978; 8(6):443–6.

164. Nissen ED, Kent DR, Nissen SE. Role of oral contraceptive agents in the pathogenesis of liver tumors. J Toxicol Environ Health 1979; 5(2–3):231–54.

165. Pasquale SA. Oral contraceptives: significance of their effects in man and relationship to findings in animal models. Toxicol Pathol 1989; 17(2):396–400.

166. Ochs H, Dusterberg B, Gunzel P, Sculte-Hermann R. Effect of tumor promoting contraceptive steroids on growth and drug metabolism enzymes in rat liver. Cancer Res 1986; 46:1224–32.

167. Kraek M, Peterson R, Sleisenger M, Jeffries G. Effects of ethinylestradiol induced cholestasis on bile flow and biliary excretion of estradiol and estradiol glucuronide by the rat. Proc Soc Exp Biol Med 1969; 131:646–50.

168. Mayol X, Pérez-Tomás R, Culleré X, Romero A, Estadella MD, Domingo J. Cell proliferation and tumour promotion by ethinyl estradiol in rat hepatocarcinogenesis. Carcinogenesis 1991; 12(6):1133–6.

169. Cameron R, Imaida K, Tsuda H, Ito N. Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res 1982; 42:2426–8.

170. Campen D, Maronpot R, Lucier G. Dose-response relationships in promotion of rat hepatocarcinogenesis by 17 alpha-ethinylestradiol. J Toxicol Environ Health 1990; 29(3):257–68

171. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell 1995; 83(6):835–9.

172. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294(5548):1866–70.

173. Desvergne B, Michalik L, Wahli W, et al. Be fit or be sick: peroxisome proliferator activated receptors are down the road. Mol Endocrinol 2004; 18:1321–32.

174. Lee S, Pineau T, Drago J, Lee E, Owens J, Kroetz D, Fernandez-Salguero P, Westphahl H, Gonzalez F. Targeted disruption of the alpha isoform of the peroxisome proliferator activated receptor gene in mice results in the abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995; 15:3012–22.

175. Issemann I, Green S. Activation of a member of the steroid hormone receptor super-family by peroxisome proliferators. Nature 1990; 347:645–50.

176. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000; 40:491–518.

177. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 2003; 33(6):655–780.

178. Reddy JK, Krishnakantha TP. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science 1975; 190(4216): 787–9.

179. Reddy JK, Moody DE, Azarnoff DL, Tomarelli RM. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther 1977; 225(1):51–7.

180. Moody DE, Rao MS, Reddy JK. Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin. Virchows Arch B Cell Pathol 1977; 23(4): 291–6.

181. Reddy JK, Rao MS, Azarnoff DL, Sell S. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res 1979; 39(1):152–61.

182. Reddy JK, Rao MS. Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J Natl Cancer Inst 1977; 59(6):1645–50.

183. Reddy JK, Rao MS. Enhancement by Wy-14,643, a hepatic peroxisome proliferator, of diethylnitrosamine-initiated hepatic tumorigenesis in the rat. Br J Cancer 1978; 38(4):537–43.

184. Rumsby PC, Davies MJ, Price RJ, Lake BG. Effect of some peroxisome proliferators on transforming growth factor-beta 1 gene expression and insulin-like growth factor II/mannose-6-phosphate receptor gene expression in rat liver. Carcinogenesis 1994; 15(2):419–21.

185. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997; 18(11):2029–33.

186. Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 2006; 27(5):1074–80.

187. Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst 1998; 90(22):1702–9.

188. Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med 2005; 83(10):774–85.

189. Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008; 246(1):2–8.

190. Green S. Peroxisome proliferators: a model for receptor mediated carcinogenesis. Cancer Surv 1992; 14:221–32.

191. Gu YZ, Hogenesch JB, Bradfield CA. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 2000; 40:519–61.

192. Schmidt JV, Bradfield CA. Ah receptor signaling pathways. Annu Rev Cell Dev Biol 1996; 12:55–89.

193. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics 1993; 3(5):213–30.

194. Connor KT, Aylward LL. Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR. J Toxicol Environ Health B Crit Rev 2006; 9(2):147–71.

195. Harper PA, Wong JY, Lam MS, Okey AB. Polymorphisms in the human AH receptor. Chem Biol Interact 2002; 141(1–2):161–87.

196. Okey AB, Franc MA, Moffat ID, Tijet N, Boutros PC, Korkalainen M, Tuomisto J, Pohjanvirta R. Toxicological implications of polymorphisms in receptors for xenobiotic chemicals: the case of the aryl hydrocarbon receptor. Toxicol Appl Pharmacol 2005; 207(2 Suppl):43–51.

197. Kociba RJ, Keyes DG, Beyer JE, Carreon RM, Wade CE, Dittenber DA, Kalnins RP, Frauson LE, Park CN, Barnard SD, Hummel RA, Humiston CG. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 1978; 46(2):279–303.

198. Poland A, Glover E. Chlorinated biphenyl induction of aryl hydrocarbon hydroxylase activity: a study of the structure-activity relationship. Mol Pharmacol 1977; 13(5): 924–38.

199. Frueh FW, Hayashibara KC, Brown PO, Whitlock JP Jr. Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression. Toxicol Lett 2001; 122(3):189–203

200. Beebe LE, Fornwald LW, Diwan BA, Anver MR, Anderson LM. Promotion of N-nitrosodiethylamine-initiated hepatocellular tumors and hepatoblastomas by 2,3,7,8-tetrachlorodibenzo-p-dioxin or Aroclor 1254 in C57BL/6, DBA/2, and B6D2F1 mice. Cancer Res 1995; 55(21):4875–80.

201. Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L, Schwarz M. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 2004; 64(14):4707–10.

202. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995; 268(5211):722–6.

203. Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 1996; 93(13):6731–6.

204. Lahvis GP, Bradfield CA.Biochem Pharmacol. Ahr null alleles: distinctive or different? 1998; 56(7):781–7

205. Yoon CY, Park M, Kim BH, Park JY, Park MS, Jeong YK, Kwon H, Jung HK, Kang H, Lee YS, Lee BJ. Gene expression profile by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the liver of wild-type (AhR+/+) and aryl hydrocarbon receptor-deficient (AhR-/-) mice. J Vet Med Sci 2006; 68(7):663–8.

206. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996; 140(1):173–9.

207. Watson MA, Devereux TR, Malarkey DE, Anderson MW, Maronpot RR. H-ras oncogene mutation spectra in B6C3F1 and C57BL/6 mouse liver tumors provide

evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. Carcinogenesis 1995; 16(8):1705–10

208. Pitot HC, Goldsworthy TL, Moran S, Kennan W, Glauert HP, Maronpot RR, Campbell HA. A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationships to altered hepatic foci. Carcinogenesis 1987; 8(10):1491–9.

209. Buchmann A, Stinchcombe S, Körner W, Hagenmaier H, Bock KW. Effects of 2,3,7,8-tetrachloro- and 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin on the proliferation of preneoplastic liver cells in the rat. Carcinogenesis 1994; 15(6):1143–50.

210. Schrenk D, Schäfer S, Bock KW. 2,3,7,8-Tetrachlorodibenzo-p-dioxin as growth modulator in mouse hepatocytes with high and low affinity Ah receptor. Carcinogenesis 1994; 15(1):27–31.

211. Münzel P, Bock-Hennig B, Schieback S, Gschaidmeier H, Beck-Gschaidmeier S, Bock KW. Growth modulation of hepatocytes and rat liver epithelial cells (WB-F344) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Carcinogenesis 1996; 17(2): 197–202.

212. Bock KW, Köhle C. Ah receptor- and TCDD-mediated liver tumor promotion: clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem Pharmacol 2005; 69(10):1403–8.

213. Stinchcombe S, Buchmann A, Bock KW, Schwarz M. Inhibition of apoptosis during 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated tumour promotion in rat liver. Carcinogenesis 1995; 16(6):1271–5.

214. Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ, Roberts AB and Gonzalez FJ. The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-β and apoptosis. Mol Pharmacol 1998; 54(2):313–21.

215. Patel RD, Hollingshead BD, Omiecinski CJ, Perdew GH. Aryl-hydrocarbon receptor activation regulates constitutive androstane receptor levels in murine and human liver. Hepatology 2007; 46(1):209–18.

216. Nukaya M, Takahashi Y, Gonzalez FJ, Kamataki T. Aryl hydrocarbon receptor-mediated suppression of GH receptor and Janus kinase 2 expression in mice. FEBS Lett 2004; 558(1–3):96–100.

217. [No authors listed]. Polychlorinated- dibenzo-dioxins. In: IARC Monographs on the evaluation of carcinogenic risk to humans. IARC, Lyon 1997; 69:33–343

218. Bertazzi PA, Bernucci I, Brambilla G, Consonni D, Pesatori AC. The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ Health Perspect 1998; 106 Suppl 2:625–33.

219. Yu ML, Guo YL, Hsu CC, Rogan WJ. Increased mortality from chronic liver disease and cirrhosis 13 years after the Taiwan "yucheng" ("oil disease") incident. Am J Ind Med 1997; 31(2):172–5.

220. Prince MM, Hein MJ, Ruder AM, Waters MA, Laber PA, Whelan EA. Update: cohort mortality study of workers highly exposed to polychlorinated biphenyls (PCBs) during the manufacture of electrical capacitors, 1940–1998. Environ Health 2006; 5:13

221. Sharma OK, Kuchino Y, Borek E. Mechanisms of ethionine carcinogenesis. Adv Enzyme Regul 1977; 16:391–405.

222. Kanduc D, Ghoshal A, Quagliariello E, Farber E. DNA hypomethylation in ethionine-induced rat preneoplastic hepatocyte nodules. Biochem Biophys Res Commun 1988; 150(2):739–44.

223. Andervont H, Dunn T. Transplantation of spontaneous and induced hepatomas in inbred mice. J Natl Cancer Inst 1952; 13(2):455–503.

224. Reuber MD. Influence of hormones on N-2-fluorenyldiacetamide-induced hyperplastic hepatic nodules in rats. J Natl Cancer Inst 1969; 43(2):445–52.

225. Tennekes H, Kaufmann W, Dammann M, van Ravenzwaay B. The stability of historical control data for common neoplasms in laboratory rats and the implications for carcinogenic risk assessment. Rugul Toxi and Pharm 2004; 40(3):293–304.

226. Dragan YP, Sargent L, Xu YD, Xu YH, Pitot HC. The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc Soc Exp Biol Med 1993; 202(1):16–24.

227. Solt DB, Medline A, Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol 1977; 88(3):595–618.

228. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008; 48(5):858–79.

229. Bannasch P. Hormonal and hormone-like effects eliciting hepatocarcinogenesis. Folia Histochem Cytobiol 2001; 39 Suppl 2:28–9.

230. Mazzantini R, de Conti A, Moreno F. Persistent and remodeling hepatic preneoplastic lesions present differences in cell proliferation and apoptosis, as well as in p53, Bcl-2 and NF-kappaB pathways. J Cell Biochem 2008; 103(2):538–46.

231. Xu C, Zhang S, Chen X, Rahman S. Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol 2007; 13(24):3323–32.

232. Ogawa K, Asamoto M, Suzuki S, Tsujimura K, Shirai T. Downregulation of apoptosis revealed by laser microdissection and cDNA microarray analysis of related genes in rat liver preneoplastic lesions. Med Mol Morphol 2005; 38(1):23–9.

233. Levinovitz A, Husman B, Eriksson L, Norstedt G, Andersson G. Decreased expression of the growth hormone receptor and growth hormone binding protein in rat liver nodules. Mol Carcinog 1990; 3(3):157–64.

234. Norstedt G, Levinovitz A, Möller C, Eriksson L, Andersson G. Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 1988; 9(2):209–13.

235. Tellgren A, Wood T, Flores-Morales A, Torndal U, Eriksson L, Norstedt G. Differentially expressed transcripts in neoplastic hepatic nodules and neonatal rat liver studied by cDNA microarray analysis. Int J Cancer 2003; 104(2):131–8.

236. Pérez-Carreón J, López-García C, Fattel-Fazenda S, Arce-Popoca E, Alemán-Lazarini L, Hernández-García S, Le Berre V, Sokol S, Francois J, Villa-Treviño S. Gene expression profile related to the progression of preneoplastic nodules toward hepatocellular carcinoma in rats. Neoplasia 2006; 8(5):373–83.

237. Dragan Y, Hully J, Nakamura J, Mass M, Swenberg J, Pitot HC. Biochemical events during initiation of rat hepatocarcinogenesis by diethylnitrosamine. Carcinogenesis 1994; 5:1451–1458.

238. Sato K, Kitahara A, Satoh K, Ishikawa T, Tatematsu M, Ito N. The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 1984; 75(3):199–202.

239. Moore MA, Nakagawa K, Satoh K, Ishikawa T, Sato K. Single GST-P positive liver cells – putative initiated hepatocytes. Carcinogenesis 1987; 8(3):483–6.

240. Cameron RG. Identification of the putative first cellular step of chemical hepatocarcinogenesis. Cancer Lett 1989; 47(3):163–7.

241. Yokota K, Singh U, Shinozuka H. Effects of a choline-deficient diet and a hypolipidemic agent on single glutathione S-transferase placental form-positive hepatocytes in rat liver. Jpn J Cancer Res 1990; 81(2):129–34.

242. Satoh K, Hatayama I, Tateoka N, Tamai K, Shimizu T, Tatematsu M, Ito N, Sato K. Transient induction of single GST-P positive hepatocytes by DEN. Carcinogenesis 1989; 10(11):2107–11.

243. Saeter G, Schwarze PE, Nesland JM, Seglen PO. Diploid nature of hepatocellular tumours developing from transplanted preneoplastic liver cells. Br J Cancer 1989; 59(2):198–205.

244. Sargent L, Xu YH, Sattler GL, Meisner L, Pitot HC. Ploidy and karyotype of hepatocytes isolated from enzyme-altered foci in two different protocols of multistage hepatocarcinogenesis in the rat. Carcinogenesis 1989; 10(2):387–91.

245. Sato K, Kitahara A, Satoh K, Ishikawa T, Tatematsu M, Ito N. The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 1984; 75(3):199–202.

246. Pitot HC. Adventures in hepatocarcinogenesis. Annu Rev Pathol 2007; 2:1–29.

247. Scherer E. Relationship among histochemically distinguishable early lesions in multistep-multistage hepatocarcinogenesis. Arch Toxicol Suppl 1987; 10:81–94.

248. Pitot HC, Campbell HA, Maronpot R, Bawa N, Rizvi TA, Xu YH, Sargent L, Dragan Y, Pyron M. Critical parameters in the quantitation of the stages of initiation, promotion, and progression in one model of hepatocarcinogenesis in the rat. Toxicol Pathol 1989; 17(4 Pt 1):594–611

249. Drinkwater N. Genetic control of hepatocarcinogenesis in C3H mice. Drug Metab Rev 1994; 26(1–2):201–8

250. Nakano H, Hatayama I, Satoh K, Suzuki S, Sato K, Tsuchida S. C-Jun expression in single cells and preneoplastic foci induced by diethylnitrosamine in B6C3F1 mice: comparison with the expression of pi-class glutathione S transferase. Carcinogenesis 1994; 15:1853–57.

251. Drinkwater N, Bennett LM Genetic control of carcinogenesis in experimental animals. In: Homburger F, (ed.), Prog Exper Tumor Res, Cambridge, MA, S Karger, 1991; 1–20

252. Bugni JM, Poole TM, Drinkwater NR. The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility. Carcinogenesis 2001; 22(11):1853–62.

253. Drinkwater NR, Hanigan MH, Kemp CJ. Genetic determinants of hepatocarcinogenesis in the B6C3F1 mouse. Toxicol Lett 1989; 49(2–3):255–65.

254. Dragani TA, Canzian F, Manenti G, Pierotti MA. Hepatocarcinogenesis: a polygenic model of inherited predisposition to cancer. Tumori 1996; 82(1):1–5.

255. Bilger A, Bennett LM, Carabeo RA, Chiaverotti TA, Dvorak C, Liss KM, Schadewald SA, Pitot HC, Drinkwater NR. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 2004; 167(2):859–66.

255a. Andervont B. Studies on the occurrence of spontaneous hepatomas in mice of strains CBH and CBA. J Natl Cancer Inst 1950; 11(1):581–92.

256. Manenti G, Galvan A, Falvella FS, Pascale RM, Spada E, Milani S, Gonzalez Neira A, Feo F, Dragani TA. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology 2008; 48(2):617–23.

257. McClain RM, Keller D, Casciano D, Fu P, MacDonald J, Popp J, Sagartz J. Neonatal mouse model: review of methods and results. Toxicol Pathol 2001; 29 Suppl:128–37.

258. Vesselinovitch SD. Infant mouse as a sensitive bioassay system for carcinogenicity of N-nitroso compounds. IARC Sci Publ 1980; 31:645–55.

259. Leenders MW, Nijkamp MW, Borel Rinkes IH. Mouse models in liver cancer research: A review of current literature. World J Gastroenterol 2008; 14(45):6915–23.

260. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S79–86.

261. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S62–71.

262. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl 1):S35–50.

263. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S72–8.

264. Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol 2003; 38(3):357–60.
265. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134(6):1655–69.
266. Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327(7407):143–7.
267. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis 2007; 17(1):63–70.
268. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11(1):74–80.
269. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21(1):17–26.
270. Erickson SK. Nonalcoholic fatty liver disease (NAFLD). J Lipid Res 2008 Dec 12.
271. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5(1):18–25.
272. Larter CZ, Yeh MM. Animal models of NASH: Getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008 Aug 21.
273. El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol 2008; 14(26):4120–6.
274. Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008 Apr 28; 14(16):2474–86.
275. Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med 2008; 19(2):75–82.
276. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132(11):1761–6.
277. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus.Semin Liver Dis 1984; 4(2):113–21.
278. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53(4):790–4.
279. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14(11):1652–6.
280. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case–control study among men. J Natl Cancer Inst 2001; 93(21):1644–51.
281. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008; 28(2):175–88.
282. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001; 22(4):535–45.
283. Groopman JD, Johnson D, Kensler TW. Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. Cancer Biomark 2005; 1(1):5–14.
284. Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res 1992; 52(7 Suppl):2114s–8s.
285. Schoental R. Trichothecenes, zearalenone, and other carcinogenic metabolites of Fusarium and related microfungi. Adv Cancer Res 1985; 45:217–90.
286. Gelderblom WC, Abel S, Smuts CM, Marnewick J, Marasas WF, Lemmer ER, Ramljak D. Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion. Environ Health Perspect 2001; 109 Suppl 2:291–300.

287. Ueno Y, Iijima K, Wang SD, Sugiura Y, Sekijima M, Tanaka T, Chen C, Yu SZ. Fumonisins as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China, by HPLC and ELISA. Food Chem Toxicol 1997; 35(12):1143–50.

288. Harada K, Oshikata M, Uchida H, Suzuki M, Kondo F, Sato K, Ueno Y, Yu SZ, Chen G, Chen GC. Detection and identification of microcystins in the drinking water of Haimen City, China. Nat Toxins 1996; 4(6):277–83.

289. Hirono I. Natural carcinogenic products of plant origin. Crit Rev Toxicol 1981; 8(3):235–77.

290. Prakash AS, Pereira TN, Reilly PE, Seawright AA. Pyrrolizidine alkaloids in human diet. Mutat Res 1999; 443(1–2):53–67.

291. Polesel J, Talamini R, Montella M, Maso LD, Crovatto M, Parpinel M, Izzo F, Tommasi LG, Serraino D, La Vecchia C, Franceschi S. Nutrients intake and the risk of hepatocellular carcinoma in Italy. Eur J Cancer 2007; 43(16):2381–7.

292. Talamini R, Polesel J, Montella M, Dal Maso L, Crispo A, Tommasi LG, Izzo F, Crovatto M, La Vecchia C, Franceschi S. Food groups and risk of hepatocellular carcinoma: A multicenter case–control study in Italy. Int J Cancer 2006; 119(12): 2916–21.

293. Yu MW, Horng IS, Hsu KH, Chiang YC, Liaw YF, Chen CJ. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Nutrients intake and the risk of hepatocellular carcinoma in Italy. Am J Epidemiol 1999; 150(4):367–74.

294. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst 2006; 98(7):482–90.

295. Yu MW, Chiang YC, Lien JP, Chen CJ. Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B1-DNA adducts in healthy males. Carcinogenesis 1997; 18(6):1189–94.

296. Naccarato R, Farinati F. Hepatocellular carcinoma, alcohol, and cirrhosis: facts and hypotheses. Dig Dis Sci 1991; 36(8):1137–42.

297. Farinati F, Fagiuoli S, de Maria N, Zotti S, Chiaramonte M, Salvagnini M, Naccarato R. Risk of hepatocellular carcinoma in alcoholic cirrhosis. Liver 1991; 11(3):190–1.

298. Seitz HK, Simanowski UA, Osswald B. Gastrointestinal carcinogenesis: ethanol as a risk factor. Eur J Cancer Prev 1992; 1 Suppl 3:5–18.

299. Miyakawa H, Sato C, Tazawa J, Izumi N, Hattori K, Ebata A, Maeda M, Ikeda T, Hirata R, Mae S, et al. A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. Alcohol Alcohol Suppl 1994; 29(1):75–9.

300. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51(20):5621–5.

301. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, Casarin P, Izzo F, Tommasi LG, Chemin I, Trépo C, Crovatto M, Talamini R. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15(4):683–9.

302. Yu MC, Yuan JM, Lu SC. Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23 Suppl 1:S92–7.

303. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with

hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case–control study. Int J Cancer 2008; 123(8):1883–91.

304. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42(2):218–24.

305. Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI, Chien-Jen C. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003; 14(3):241–50.

306. Austin H. The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. In: Tabor E, DiBisceglie A, Purcell R, (eds.), Etiology, pathology and treatment of hepatocellular carcinoma in North America, vol. 13. The Woodlands, Texas: Portfolio Publishing Company, 2007; 57–70.

307. [No authors listed] International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans: tobacco smoke and involuntary smoking, Lyon, France, IARC, 2004; 83; 161–76.

308. Grangé JD, Guéchot J, Legendre C, Giboudeau J, Darnis F, Poupon R. Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology 1987; 93(6):1409–13.

309. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet 1977; 2(8032):262–3.

310. Gorayski PM, Thomas AC, Thompson CH, Subhash HS. Hepatocellular carcinoma associated with recreational anabolic steroid use. Br J Sports Med 2008; 42(1):74–5.

311. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004; 77(3):257–67.

312. Carrasco D, Prieto M, Pallardó L, Moll JL, Cruz JM, Muñoz C, Berenguer J. Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature. J Hepatol 1985; 1(6):573–8.

313. McCaughan GW, Bilous MJ, Gallagher ND. Long-term survival with tumor regression in androgen-induced liver tumors. Cancer 1985; 56(11):2622–6.

314. Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2(7835):926–9.

315. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993; 67(3):635–7.

316. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86(2):180–2.

317. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242(7):644–8.

318. Forman D, Doll R, Peto R. Trends in mortality from carcinoma of the liver and the use of oral contraceptives. Br J Cancer 1983; 48(3):349–54.

319. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983; 48(3):437–40.

320. Fiel MI, Min A, Gerber MA, Faire B, Schwartz M, Thung SN. Hepatocellular carcinoma in long-term oral contraceptive use. Liver 1996; 16(6):372–6.

321. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16(5):491–4.

322. Wallace DF, Subramaniam VN. Co-factors in liver disease: The role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta 2008 Sep 20

323. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal

GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13(4): 399–408.

324. Cassiman D, Vannoote J, Roelandts R, Libbrecht L, Roskams T, Van den Oord J, Fevery J, Garmyn M, Nevens F. Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single centre and review of the literature. Acta Gastroenterol Belg 2008; 71(2):237–42.

325. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998; 27(6):1563–6.

326. von Delius S, Lersch C, Schulte-Frohlinde E, Fend F, Dobritz M, Schmid RM, Eckel F. Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver. Z Gastroenterol 2006; 44(1):39–42.

327. Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Jiang J, Fei Y, Brunt EM, Ruddy DA, Prass CE, Schatzman RC, O'Neill R, Britton RS, Bacon BR, Sly WS. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 1998; 95(5):2492–7.

328. Miranda CJ, Makui H, Andrews NC, Santos MM. Contributions of beta2-microglobulin-dependent molecules and lymphocytes to iron regulation: insights from HfeRag1(-/-) and beta2mRag1(-/-) double knock-out mice. Blood 2004; 103(7): 2847–9.

329. Gross CN, Irrinki A, Feder JN, Enns CA. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. J Biol Chem 1998; 273(34):22068–74.

330. Beckman LE, Hägerstrand I, Stenling R, Van Landeghem GF, Beckman L. Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. Oncology 2000; 59(4):317–22.

331. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33(3):647–51.

332. Blanc JF, De Ledinghen V, Bernard PH, de Verneuil H, Winnock M, Le Bail B, Carles J, Saric J, Balabaud C, Bioulac-Sage P. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000; 32(5):805–11.

333. Hellerbrand C, Pöppl A, Hartmann A, Schölmerich J, Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 2003; 1(4):279–84.

334. Fracanzani AL, Fargion S, Stazi MA, Valenti L, Amoroso P, Cariani E, Sangiovanni A, Tommasini M, Rossini A, Bertelli C, Fatta E, Patriarca V, Brescianini S, Stroffolini T. Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis 2005; 35(1):27–32.

335. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, Korenaga M, Xiao SY, Weinman SA, Lemon SM, Sakaida I, Okita K. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130(7):2087–98.

336. Morcos M, Dubois S, Bralet MP, Belghiti J, Degott C, Terris B. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol 2001; 116(5):738–43.

337. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. p53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 1999; 117(1):154–60.

338. Lehmann U, Wingen LU, Brakensiek K, Wedemeyer H, Becker T, Heim A, Metzig K, Hasemeier B, Kreipe H, Flemming P. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet 2007; 16(11):1335–42.

339. Iwadate H, Ohira H, Suzuki T, Abe K, Yokokawa J, Takiguchi J, Rai T, Orikasa H, Irisawa A, Obara K, Kasukawa R, Sato Y. Hepatocellular carcinoma associated with Wilson's disease. Intern Med 2004; 43(11):1042–5.

340. Sugeno H, Takebayashi Y, Higashimoto M, Ogura Y, Shibukawa G, Kanzaki A, Terada K, Sugiyama T, Watanabe K, Katoh R, Nitta Y, Fukushima T, Koyama Y, Inoue N, Sekikawa K, Ogawa K, Sato Y, Takenoshita S. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma. Anticancer Res 2004; 24(2C):1045–8.

341. Sawaki M, Enomoto K, Takahashi H, Nakajima Y, Mori M. Phenotype of preneoplastic and neoplastic liver lesions during spontaneous liver carcinogenesis of LEC rats. Carcinogenesis 1990; 11(10):1857–61.

342. Wu J, Forbes JR, Chen HS, Cox DW. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 1994; 7(4):541–5.

343. Theophilos MB, Cox DW, Mercer JF. The toxic milk mouse is a murine model of Wilson disease. Hum Mol Genet 1996; 5(10):1619–24.

344. Buiakova OI, Xu J, Lutsenko S, Zeitlin S, Das K, Das S, Ross BM, Mekios C, Scheinberg IH, Gilliam TC. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet 1999; 8(9):1665–71.

345. Billingsley GD, Walter MA, Hammond GL, Cox DW. Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1. Am J Hum Genet 1993; 52(2):343–53.

346. Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103(8):2136–41.

347. Eriksson S. Alpha 1-antitrypsin deficiency. J Hepatol 1999; 30 Suppl 1:34–9.

348. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 1986; 314(12):736–9.

349. Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998; 22(6):742–8.

350. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996; 8(10):989–94.

351. Smanadhikorn P, Pongpaew P, Srivatanakul P, Tungtrongchitr R, Supanaranond W, Schelp FP, Migasena P. alpha 1-antitrypsin phenotype PiMZ, a risk factor for liver cirrhosis but not for liver cancers in Thailand. Southeast Asian J Trop Med Public Health 1995; 26(2):240–2.

352. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 1977; 74(10):4641–5.

353. Santra S, Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 2008; 9(7):1229–36.

354. Grompe M, al-Dhalimy M. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat 1993; 2(2):85–93.

355. Grompe M, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993; 7(12A):2298–307.

356. Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, Ou CN, Finegold M. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995; 10(4):453–60.

357. Al-Dhalimy M, Overturf K, Finegold M, Grompe M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002; 75(1):38–45.

358. Nakamura K, Tanaka Y, Mitsubuchi H, Endo F. Animal models of tyrosinemia. J Nutr 2007; 137(6 Suppl 1):1556S–60S.

359. Lee B, Goss J. Long-term correction of urea cycle disorders. J Pediatr 2001; 138(1 Suppl):S62–71.

360. Scaglia F, Brunetti-Pierri N, Kleppe S, Marini J, Carter S, Garlick P, Jahoor F, O'Brien W, Lee B. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J Nutr 2004; 134(10 Suppl):2775S–82S

361. Engel K, Höhne W, Häberle J. Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. Hum Mutat 2008 Nov 12.

362. Patejunas G, Bradley A, Beaudet AL, O'Brien WE. Generation of a mouse model for citrullinemia by targeted disruption of the argininosuccinate synthetase gene. Somat Cell Mol Genet 1994; 20(1):55–60.

363. Ye X, Whiteman B, Jerebtsova M, Batshaw ML. Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA. Gene Ther 2000; 7(20):1777–82.

364. Komatsu M, Yazaki M, Tanaka N, Sano K, Hashimoto E, Takei Y, Song YZ, Tanaka E, Kiyosawa K, Saheki T, Aoyama T, Kobayashi K. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J Hepatol 2008; 49(5): 810–20.

365. Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J Hum Genet 2002; 47(7):333–41.

366. Sawada S, Kinjo T, Makishi S, Tomita M, Arasaki A, Iseki K, Watanabe H, Kobayashi K, Sunakawa H, Iwamasa T, Mori N. Downregulation of citrin, a mitochondrial AGC, is associated with apoptosis of hepatocytes. Biochem Biophys Res Commun 2007; 364(4):937–44.

367. Sinasac DS, Moriyama M, Jalil MA, Begum L, Li MX, Iijima M, Horiuchi M, Robinson BH, Kobayashi K, Saheki T, Tsui LC. Slc25a13-knockout mice harbor metabolic deficits but fail to display hallmarks of adult-onset type II citrullinemia. Mol Cell Biol 2004; 24(2):527–36.

368. Saheki T, Iijima M, Li MX, Kobayashi K, Horiuchi M, Ushikai M, Okumura F, Meng XJ, Inoue I, Tajima A, Moriyama M, Eto K, Kadowaki T, Sinasac DS, Tsui LC, Tsuji M, Okano A, Kobayashi T. Citrin/mitochondrial glycerol-3-phosphate dehydrogenase double knock-out mice recapitulate features of human citrin deficiency. J Biol Chem 2007; 282(34):25041–52.